CA2473797A1 - Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders - Google Patents

Abstract

Combinations of aldosterone blockers and NSAIDs useful in the treatment of inflammation are disclosed.

Description

ALDOSTERONE ANTAGONIST AND NON-STEROIDAL ANTI
INFLAMMATORY AGENT COMBINATION THERAPY TO PREVENT OR
TREAT CARDIOVASCULAR DISORDERS
Field of the Invention This invention is in the field of preventing or treating cardiovascular disorders. More specifically, this invention relates to the use of aldosterone antagonist and non-steroidal anti-inflammatory drug (NSAID) combination therapy in preventing or treating cardiovascular disease including atherosclerosis.
Background of the Iaventioa Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG~, PGH2 and PGE2~ has been a common target of anti-inflammatory drug discovery. However, common non-steroidal anti-inflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAID's can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAID's is the use of corticosteroids, which also produce severe adverse effects, especially when long term therapy is involved.
NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). Recently an inducible enzyme associated with inflammation (named "cyClooxygenase-2 (COX-2)" or "prostaglandin G/H
synthase II") was discovered.
Several studies have suggested that inflammation plays a role in cardiovascular diseases. For example, Ridker et al. (New Eng. J. Med., 336, 973-9 (1997)) describes a possible role of inflammation in cardiovascular disease. J. Boyle (J. Path., 181, 93-9 (1997)) describes the association of plaque rupture and atherosclerotiC inflammation.
In the treatment or prevention of cardiovascular disorders, present drug therapies are not always effective or well tolerated by the subjects undergoing therapy. Accordingly new drug therapies are necessary to fill this need. The present invention is therefore directed to a novel drug therapy employing a combination of an aldosterone antagonist and NSAID to treat or prevent cardiovascular disorders. More specifically, this invention relates to the use of aldosterone antagonist and NSAID combination therapy in preventing or treating cardiovascular disorders.
Brief Description of the Drawings Fig. 1 shows changes in systolic blood pressure in angiotensin II infused rat study.
Fig. 2 shows prevention by eplerenone (epoxymexrenone) of vascular inflammation in the heart of angiotensin II infused rats.
Fig. 3 shows lack of cyclooxygenase-2 (COX-2) expression in the heart of a vehicle infused rat.
Fig. 4 shows induction of COX-2 expression in heart of Ang II infused rat.

Fig. 5 shows prevention by eplerenone of induction of COX-2 expression in heart of Ang II infused rat.
Fig. 6 shows lack of osteopontin expression in the heart of a vehicle infused rat.
Fig. 7 shows prevention by eplerenone of induction of osteopontin expression in heart of aldosterone infused rat.
Fig. 8 shows prevention by eplerenone of osteopontin upregulation in myocardium of aldosterone infused rats.
Fig. 9 shows prevention by eplerenone of COX-2 upregulation in myocardium of aldosterone infused rats.
Fig. 10 shows prevention by eplerenone of myocardial injury in aldosterone infused rats.
Fig. 11 shows upregulated co-expression of C0X-2 and osteopontin in coronary artery media of aldosterone infused rat.
Fig. 12 shows.some of the mechanisms for aldosterone-induced vascular inflammation and injury.
Fig. 13 shows inhibition of increased urinary protein excretion by eplerenone treatment in angiotensin II infused, captopril treated stroke prone spontaneously hypertensive rats.
Fig. 14 shows reduction in histopathological scores for renal injury with eplerenone treatment in angiotensin II infused, captopril treated stroke prone spontaneously hypertensive rats.
Fig. 15 shows increased survival and reduced cerebral injury with eplerenone~ treatment in stroke-prone spontaneously hypertensive rats.
Fig. 16 shows decrease in cerebral injury with eplerenone treatment in stroke-prone spontaneously hypertensive rats.

Fig. 17 shows inhibition of early time-course expression of myocardial COX-2 in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 18 shows inhibition of early time-course expression of myocardial osteopontin in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 19 shows inhibition of early time-course expression of myocardial MCP-1 in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 20 shows inhibition of early time-course expression of myocardial ICAM-1 and VCAM-1 in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 2l shows systolic blood pressure elevation with aldosterone infusion, and depression of this elevation with aldosterone infusion and eplerenone treatment. °
Fig. 22 shows myocardial histopathology scores at 28 days for control rats, for rats infused with aldosterone, and for rats infused with aldosterone and treated with eplerenone, and the ratio of heart weight to body weight for rats infused with aldosterone, and for rats infused with aldosterone and treated with eplerenone.
Fig. 23 shows 28 day circulating osteopontin levels for control rats, for rats infused with aldosterone, and for rats infused with aldosterone and treated with eplerenone.
Fig. 24 shows the relative mRNA expression at 28 days for inflammatory cytokines in control rats, in rats infused with aldosterone, and in rats infused with aldosterone and treated with eplerenone.

Detailed Description of the Invention The present invention provides a method for 5 preventing or treating cardiovascular disorders in a subject in need thereof. The method comprises treating the subject with a therapeutically effective amount of an aldosterone receptor antagonist (including, but not limited to, derivatives or pharmaceutically-acceptable salts thereof) in combination with a NSAID (including, but not limited to, derivatives or pharmaceutically-acceptable salts thereof).
The method above would be useful for, but not limited to, preventing or treating inflammation-related disorders in a subject, including but not limited to inflammation-related disorders of the heart, kidney and brain, particularly vascular inflammation-related disorders. The method would be useful for prevention or treatment of hypertension, heart failure, heart failure folloing myocardial infarction, congestive heart failure, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, including venous thrombosis, angina including unstable angina, calcification (such as vascular calcification and valvar calcification), Kawasaki disease and inflammation (such as coronary plaque inflammation, bacterial-induced inflammation including Chlamydia-induced inflammation and viral induced inflammation).

The method is useful for, but not limited to, treating or preventing inflammation-related disorders by altering the expression of one or more expression products that directly or indirectly regulate inflammation. Inflammation-related disorders, particularly inflammation-related cardiovascular disorders, may be mediated, in whole or in part, by one or more expression products, which may undergo increased or decreased expression. Said expression products may include but are not limited to organic molecules, proteins, DNA-based or RNA-based molecules, and networks or aggregates of such products, acting together or alone, to directly or indirectly produce an effect.
Changes in patterns of expression of said expression products may occur sequentially or simultaneously, involving two or more expression products. These expression products may have direct or indirect affects on the tissues or organs of the subject, inducing or amplifying a pathological effect induced by other molecules, or expression products. These expression products may produce pro-inflammatory effects by increased expression or decreased expression, depending on their function as pro-inflammatory or anti-inflammatory expression products, respectively.
The method is particularly useful for treating or preventing conditions by moderating 'the upregulation of pro-inflammatory components found in affected tissues, including cyclooxygenase and osteopontin, while also inhibiting the activity of cyclooxygenase in the kidney, particularly the macula densa where aldosterone antagonism can induce expression of cyclooxygenase.
While the use of an aldosterone antagonist leads to a reduction in cyclooxygenase expression induced by an inflammation-related disorder, it may not completely prevent cyclooxygenase activity. The co-action of adding an NSAID that inhibits cyclooxygenase activity will also lead to a reduction in inflammation of the affected tissue or organ. The use of an aldosterone antagonist can induce upregulation of cyclooxygenase in the macula densa and cortical thick ascending limb (CTAL) of Henle's loop in the kidney. In the kidney, prostaglandins, the product of cyclooxygenase, are involved in the regulation of renal hemodynamics and saltwater homeostasis. As a result the non-inflammatory aldosterone antagonist induction of cyclooxygenase in the macula densa and CTRL region of the kidney can lead to pathological effects such as increased blood pressure and retention of salt and water. Accordingly, co-administration of a NSAID that inhibits cyclooxygenase, with an aldosterone antagonist, will slow, stop, or reverse the progression of the pathological renal response to the aldosterone antagonist induction of cyclooxygenase in the kidney.
In the method above, cardiovascular disorder includes, but is not limited to, those disorders which are known to have an inflammation component and those that may be mediated by aldosterone or cyclooxygenase or both. The method above also includes treatment of patients with an aldosterone antagonist and NSAID
combination requiring moderation of the upregulated expression of cyclooxygenase or osteopontin. In tissues, including but not limited to the kidney, heart, and brain, cyclooxygenase may be induced resulting~in upregulated expression of this pro-inflammatory enzyme, which can cause mild to severe tissue and organ damage.

In the method above, administration of an aldosterone antagonist and NSAID combination is used to moderate the upregulated expression of cyclooxygenase. The method above would also be useful for preventing or treating conditions which may arise in tissues, including but not limited to the kidney, heart, and brain, wherein the upregulated expression of the pro-inflammatory protein osteopontin, may be induced, resulting in mild to severe tissue and organ damage. In the method above, administration of an aldosterone antagonist and NSAID
combination is used to moderate the upregulated expression of osteopontin.
In another embodiment, the present invention would be useful in preventing or treating conditions in tissues and organs, including but not limited to the kidney, heart and brain, wherein the upregulated expression of any one of the pro-inflammatory expression products MCP-1, IL-1, IL-6, VCAM-1 and ICAM-1 may occur, resulting in mild to severe tissue and organ damage. In the method above, administration of an aldosterone antagonist and NSAID combination is used to moderate the upregulated expression of any one of MCP-1, IL-1, IL-6, VCAM-1 and ICAM-1.
Non-limiting examples of expression products, whose expression can be moderated to reduce inflammation-related cardiovascular disease by treatment with an aldosterone antagonist and NSAID combination, are shown in Figure 24. Non-limiting examples of pro-inflammatory expression products that may be upregulated include one or more of the following:
(a) receptors for angiotensin II and~endothelin, (b) monocyte activating molecules avf~3 (adhesion, proliferation, migration) and CD44 (migration), (c) mediators of vascular inflammation interferon-'y (Inf-'y) , interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a), (d) NADH/NADPH oxidase to produce tissue damaging superoxide radicals, and (e) prothrombotic plasminogen activator inhibitor-1 (PAI-1) causing a decrease in active tissue plasminogen activator (t-PA).
In another embodiment of the present invention, non-limiting examples of expression products, whose expression can be moderated to reduce inflammation-related cardiovascular disease by treatment with an aldosterone antagonist and NSAID combination, include one or more of the following:
acute phase reactants like C-reactive protein ( CRP ) , pleiotropic cytokines like interleukin-6 (IL-6), IL-10, IL-12, soluble intracellular adhesion molecule-1 (sICAM-1), troponin T or I, heat shock protein 65 (HSP65), amyloid, phospholipase A2, fibrinogen, CD40/CD40L
signaling pathway and adhesion mediators like collagen-binding integrins alf~1 (mesenchymal cells) and a2f31 (epithelial cells).
In another embodiment of the present invention, one or more of the inflammation-related expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 10%. In another embodiment, said expression products can be moderated or altered by combination therapy of an 5 aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 25%. In another embodiment, said expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an 10 increase or decrease in expression of at least 50%. In another embodiment, said expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 100%.
Inhibitors of the cyclooxygenase pathway in the metabolism of arachidoniC acid used in the prevention of cardiovascular disorder may inhibit enzyme activity through a variety of mechanisms. By the way of example, the inhibitors used in the methods described herein may inhibit expression of the enzyme activity. Blocking expression of Cyclooxygenase-2, at the site of inflammatory damage, using an aldosterone antagonist, is highly advantageous in that it minimizes the gastric side effects that can occur with non-selective NSAID's, especially where prolonged prophylactic treatment at a high dose of NSAID is expected.
Dosages and Treatment Regimen The amount of aldosterone receptor antagonist blocker that is administered and the dosage regimen for the methods of this invention depend on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the pathogenic effect, the route and frequency of administration, and the particular aldosterone blocker employed, and thus may vary widely. A daily dose administered to a subject of about 0.001 to 30 mg/kg body weight, preferably between about 0.005 and about 20 mg/kg body weight, more preferably between about 0.01 and about 15 mg/kg body weight, still more preferably between about 0.05 and about 10 mg/kg body weight, and most preferably between about 0.01 to 5 mg/kg body weight, may be appropriate.
The daily dose of aldosterone antagonist administered to a human subject typically will range from about 0.1 mg to about 2000 mg. In one embodiment of the present invention, the daily dose range is from about 0.1 mg to about 400 mg. In another embodiment of the present invention, the daily dose range is from about 1 mg to about 200 mg. In a further embodiment of the present invention, the daily dose range is from about 1 mg to about 100 mg. In another embodiment of the present invention, the daily dose range is from about 10 mg to about 100 mg. In a further embodiment of the present invention, the daily dose range is from about 25 mg to about 100 mg. In another embodiment of the present invention, the daily dose is selected from the group consisting of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg. In a further embodiment of the present invention, the daily dose is selected from the group consisting of 25 mg, 50 mg, and 100 mg. A daily dose of aldosterone blocker that produces no substantial diuretic and/or anti-hypertensive effect in a subject is specifically embraced by the present method. The daily dose can be administered in one to four doses per day.
Dosing of the aldosterone blocker can be determined and adjusted based on measurement of blood pressure or appropriate surrogate markers (such as natriuretic peptides, endothelins, and other surrogate markers discussed below). Blood pressure and/or surrogate marker levels after administration of the aldosterone blocker can be compared against the corresponding baseline levels prior to administration of the aldosterone blocker to determine efficacy of the present method and titrated as needed. Non-limiting examples of surrogate markers useful in the method are surrogate markers for renal and cardiovascular disease.
Prophylatic Dosing It is beneficial to administer the aldosterone blocker prophylatically, prior to a diagnosis of said inflammation-related cardiovascular disorders, and to continue administration of the aldosterone blocker during the period of time the subject is susceptible to the inflammation-related cardiovascular disorders.
Individuals with no remarkable clinical presentation but that are nonetheless susceptible to pathologic effects therefore can be placed upon a prophylatic dose of an aldosterone blocking compound. Such prophylactic doses of the aldosterone blocker may, but need not, be lower than the doses used to treat the specific pathogenic effect of interest.
Cardiovascular Pathology Dosing Dosing to treat pathologies of cardiovascular function can be determined and adjusted based on measurement of blood concentrations of natriuretic peptides. Natriuretic peptides are a group of structurally similar but genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Atrial natriuretic peptide ("ANP") and brain natriuretic peptide ("BNP") are of myocardial cell origin and C-type natriuretic peptide ("CNP") is of endothelial origin. ANP and BNP bind to the natriuretic peptide-A receptor ("NPR-A"), which, via 3', 5'-cyclic guanosine monophosphate (cGMP), mediates natriuresis, vasodilation, renin inhibition, antimitogenesis, and lusitropic properties. Elevated natriuretic peptide levels in the blood, particularly blood BNP levels, generally are observed in subjects under conditions of blood volume expansion and after vascular injury such as acute myocardial infarction and remain elevated for an extended period of time after the infarction. (Uusimaa et al.: Int. J. Cardiol 1999; 69:
5-14) .
A decrease in natriuretic peptide level relative to the baseline level measured prior to administration of the aldosterone blocker indicates a decrease in the pathologic effect of aldosterone and therefore provides a correlation with inhibition of the pathologic effect.
Blood levels of the desired natriuretic peptide level therefore can be compared against the corresponding baseline level prior to administration of the aldosterone blocker to determine efficacy of the present method in treating the patologic effect. Based upon such natriuretic peptide level measurements, dosing of the aldosterone blocker can be adjusted to reduce the cardiovascular pathologic effect.

Similarly, cardiac pathologies can also be identified, and the appropriate dosing determined, based on circulating and urinary cGMP Levels. An increased plasma level of cGMP parallels a fall in mean arterial pressure. Increased urinary excretion of cGMP is correlated with the natriuresis.
Cardiac pathologies also can be identified by a reduced ejection fraction or the presence of myocardial infarction or heart failure or left ventricular hypertrophy. Left ventricular hypertrophy can be identified by echo-cardiogram or magnetic resonance imaging and used to monitor the progress of the treatment and appropriateness of the dosing.
In another embodiment of the invention, therefore, the methods of the present invention can be used to reduce natriuretic peptide levels, particularly BNP
levels, thereby also treating related cardiovascular pathologies.
Renal Pathology Dosing Dosing to treat pathologies of renal function can be determined and adjusted based on measurement of proteinuria, microalbuminuria, decreased glomerular filtration rate (GFR), or decreased creatinine clearance. Proteinuria is identified by the presence of greater than 0.3 g of urinary protein in a 24 hour urine collection. Microalbuminuria is identified by an increase in immunoassayable urinary albumin. Based upon such measurements, dosing of the aldosterone blocker can be adjusted to reduce the renal pathologic effect.

Neuropathy Pathology Dosing Neuropathy, especially peripheral neuropathy, can be identified by and dosing adjustments based on, neurologic exam of sensory deficit or sensory motor 5 ability.
Retinopathy Pathology Dosing Retinopathy can be identified by, and dosing adjustments based on, ophthalmologic exam.
Inflammation Markers Certain markers may be indicative of or responsible for inflammation, or pre-inflammatory conditions.
Measurement of these markers may be useful in determination of an appropriate dosage of aldosterone blocker to be administered, or determination of an efficatious dose of an aldosterone blocker after administration. Non-limiting examples of such markers are: osteopontin; acute phase reactants such as C
reactive protein (CRP), fibrinogen, Factor VIII, serum copper (carrier protein ceruloplasmin), serum iron (carrier protein ferritin), Plasminogen activator Inhibitor-1 (PAI-1) and lipoprotein(a); natriuretic peptides; endothelins; VCAM-l; ICAM-1; IL-1,Q; TNF-cx; IL-6; COX-2; fractalkine; MCP-1; and triglyceride.
NSAIDs useful in the present invention include compounds listed in Table 1 (including derivatives of these compounds). Each published document listed in Table 1 describes selected aspects of the NSAID, such as the chemical preparation or the biological properties of such compound. The content of each of these documents is incorporated herein by reference.
Table 1: NSAIDs REFERENCE

COMPOUND NAME CHEMICAL

NAME/CAS

acetaminophen US 3125598 benoxaprofen US 3912748 a carprofen US 3896145 diclofenac 15307-86-5 US 3778470 diflunisal FR 1522570 Etodolac 1,8-diethyl-1,3,4,9-GB 1391005 fenoprofen tetrahydropyrano[3,4-b]indole-1-acetic acid /41340-fenoprofen 31879-05-7 US 3649679 fh~rbiprofen (alphaR)-2-fluoro-alpha-,EP 103265 methyl-[1,1'-biphenyl]-4-acetic acid/ 5104-49-4 --- ibuprofen - alpha-methyl-4-(2- GB 1538636 methylpropyl)benzeneacetic acid 2-methoxyphenyl ester/

indomethacin 53-86-1 US 3161654 ketoprofen (R)-3-benzoyl-alpha-GB 1164585 methylbenzeneacetic acid/

I~etorolac (+,-)-5-benzoyl-2,3-dihydro-GB 1554057 1 H-pyrrolizine-1-carboxylic acid/ 74103-06-3 meclofenamate mefenamic acid US 3294813 nabumetone 4-(6-methoxy-2-naphthyl)-2-GB 1476721 butanone/ 42924-53-8 Naproxen 22204-53-1 US 3637767 oxaprozin 4,5-diphenyl-2- GB 1206403 oxazolepropanoic acid /

oxyphenbutazone US 3482021 henylbutazone US 3265577 piroxicam 3-phenyl-propenoic EP 79639 acid, 2-methyl-3-[(2-pyridinylamino)-carbonyl]-2 H-1,2-benzothiazin-4-yl ester, S,S-dioxide/ 36322-90-4 Sulindac 38194-50-2 US 3692651 Suprofen US 4035376 Tenidap (Z)-5-chloro-2,3-dihydro-3-EP 156603 (hydroxy-2-thienylmethylene)-2-oxo-1 H-indole-1-carboxamide 1120210-48-2 Tolmetin 26171-23-3 US 3752826 zomepirac US 3752826 Aspirin In one embodiment, the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.
In another embodiment, the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, and flurbiprofen.
In another embodiment, the NSAID is selected from the group consisting of ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, and oxaprozin.
In another embodiment, the NSAID is selected from the group consisting of oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.
The term "NSAID" includes any compounds (such as derivatives and pharmaceutically acceptable salts), which are structurally related to a NSAID and which possess the substantially equivalent biologic activity.
By way of example, such compounds may include, but are not limited to, prodrugs thereof.

The term "aldosterone receptor antagonist" or "aldosterone antagonist" denotes a compound capable of binding to an aldosterone receptor, as a competitive 5' inhibitor of the action of aldosterone itself at the receptor site, so as to modulate the receptor-mediated activity of aldosterone.
Aldosterone Antagonists The aldosterone antagonists used in the methods of the present invention generally are spirolactone-type steroidal compounds. The term "spirolactone-type" is intended to characterize a structure comprising a lactone moiety attached to a steroid nucleus, typically at the steroid "D" ring, through a spiro bond configuration. A subclass of spirolactone-type aldosterone antagonist compounds consists of epoxy-steroidal aldosterone antagonist compounds such as eplerenone. Another subclass of spirolactone-type antagonist compounds consists of non-epoxy-steroidal aldosterone antagonist compounds such as spironolactone.
The epoxy-steroidal aldosterone antagonist compounds used in the method of the present invention generally have a steroidal nucleus substituted with an epoxy-type moiety. The term "epoxy-type" moiety is intended to embrace any moiety characterized in having an oxygen atom as a bridge between two carbon atoms, examples of which include the following moieties:

O O O
~CH~ CH2 epoxyethyl 1,3-epoxypropyl 1,2-epoxypropyl The team "steroidal", as used in the phrase "epoxy-steroidal", denotes a nucleus provided by a cyclopenteno-phenanthrene moiety, having the conventional "A", "B", "C" and "D" rings. The epoxy-type moiety may be attached to the cyclopentenophenanthrene nucleus at any attachable or substitutable positions, that is, fused to one of the rings of the steroidal nucleus or the moiety may be l0 substituted on a ring member of the ring system. The phrase "epoxy-steroidal" is intended to embrace a steroidal nucleus having one or a plurality of epoxy-type moieties attached thereto.
Epoxy-steroidal aldosterone antagonists suitable for use in the present methods include a family of compounds having an epoxy moiety fused to the °C" ring of the steroidal nucleus. Especially preferred are 20-spiroxane compounds characterized by the presence of a 9 a,lloc-substituted epoxy moiety. Compounds 1 through 11, Table 1 below, are illustrative 9oc,110c-epoxy-steroidal compounds that may be used in the present methods. These epoxy steroids may be prepared by procedures described in Grob et al., U.S. Patent No.
4,559,332. Additional processes for the preparation of 9,11-epoxy steroidal compounds and their salts are disclosed in Ng et al., W097/21720 and Ng et al., W098/25948.
TABLE 2: Aldosterone Receptor Antagonist Compound # Structure and Name O
O
1 s ~R
0:~~ R i c~Me , R
M R H OMe O
O
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,Y-lactone, methyl ester, (7a, 11a, 17(3) -OMe Me ~ OOH
R H S R
S
R
~MR RH
,,~ OMe O
O
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,dimethyl ester,(7a,11a,17(3)-T~TA

3'H-Cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, 'y-lactone, (6(3, 7(3, 11a, 17(3) -~+
R
R~
~MR H
~,~ OPr-i O
O
Pregn-4-ene-7,21-dicarboxyliC acid,9,11-epoxy-17-hydroxy-3-oxo-,7-(1-methylethyl) ester, monopotassium salt, (7a, 11a, 17(3) -Me OH C02H
R S R
MR RH .K+
S'R
OMe O
O
Pregn-4-ene-7,21-dicarboxyliC acid,9,11-epoxy-17-hydroxy-3-oxo-,7-methylethyl) ester,monopotassium salt, (7a, 11a, 17(3) -Me R-. /~
Me ~a S p- ' O
S
S ~~ ~~.
S. H H
O
3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid,9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, 'y-lactone (6(3, 7[3, 11a) -O
3'H-cyclopropa[6,7]pregna-4,6-dime-2l-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6(3, 7(3, lla,, 17(3) -Me HO
COZH
Me R ~~a '~~
' S
S
S ~~
~t/I H H ~ I~
O
3'H-cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6~i, 7(3, 11a, 17(3) -Me R.~ ~~~.~0~ O
Me S
S
S. H H
O
3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-,y-lactone (6~i,7~3,11a,17(3)-O
O
S 'R
R H Me S' ' Me K H OE t R
O
O
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,y-lactone, ethyl ester, (7a,11a,17(3)-O
11 S 'R
R H ~Me S ~ R
K
~M R H
O P r-i O
O
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,y-lactone, 1-methylethyl ester (7a,11a, 17(3)-Of particular interest is the compound eplerenone (also known as: epoxymexrenone and CGP 30 083) which is compound 1 as shown above. The chemical name for eplerenone is pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 'y-lactone, methyl ester, (7cx, llcx, l7cx) -. This chemical name corresponds to the CAS
registry name for eplerenone (the CAS registry number for eplerenone is 107724-20-9). U.S. Patent No.
4,559,332 identifies eplerenone by the alternative name of 9cx, llcx-epoxy-7cx-methoxycarbonyl-20-spirox-4-ene-3 , 21-dione. Such "spiroxane" nomenclature is further described, for example, at column 2, line 16 through column 4, line 48 of U.S. Patent No. 4,559,332.
Eplerenone is an aldosterone receptor antagonist and has a higher specificity for aldosterone receptors than does, for example, spironolactone. Selection of eplerenone as the aldosterone antagonist in the present method would be beneficial to reduce certain side-effects such as gynecomastia that occur with use of aldosterone antagonists having less specificity.
Non-epoxy-steroidal aldosterone antagonists suitable for use in the present methods include a family of spirolactone-type compounds defined by Formula I:

--n (I) wherein ~ ~ is C6 '~ C7 C o ~~ SCOR, wherein R is lower alkyl of up to 5 carbon atoms, and wherein ~ C15" C1 G is \~ ~ ~. ~ 0r ~~
C ' C

Lower alkyl residues include branched and unbranched groups, preferably methyl, ethyl and n-propyl.
10 Specific compounds of interest within Formula I are the following:
7a-acetylthio-3-oxo-4,15-androstadiene-[17((3-1')-spiro-5']perhydrofuran-2'-one;
3-oxo-7a-propionylthio-4,15-androstadiene-[17(((3-15 1')-spiro-5']perhydrofuran-2'-one;
6(3, 7(3-methylene-3-oxo4, 15-androstadiene- [17 ( ((3-1' ) -spiro-5']perhydrofuran-2'-one;
15a,16a-methylene-3-oxo-4,7a-propionylthio-4-androstene [17 ((3-1' ) -spiro-5' ] perhydrofuran-2' -one;
20 6(3, 7(3, 15a, 16a-dimethylene-3-oxo-4-androstene [17 ((3-1')-spiro-5']-perhydrofuran-2'-one;
7a-acetylthio-15(3,16(3-Methylene-3-oxo-4-androstene-[17 ((3-1' ) -spiro-5' ] perhydrofuran-2' -one;
15(3, 16(3-methylene-3-oxo-7(3-propionylthio-4-25 androstene-[17((3-1')-spiro-5']perhydrofuran-2'-one; and 6(3, 7(3, 15(3, 163-dimethylene-3-oxo-4-androstene- [17 ((3-1')-spiro-5']perhydrofuran-2'-one.

Methods to make compounds of Formula I are described in U.S. Patent No. 4,129,564 to Wiechart et al. issued on 12 December 1978.
Another family of non-epoxy-steroidai compounds of interest is defined by Formula II:
wherein R1 is Cl_3-alkyl or Cl_3 aryl and R2 is H or Cl_3-alkyl .
Specific compounds of interest within Formula II
are the following:
la,-acetylthio-15(3, 16(3-methylene-7a-methylthio-3-oxo-17a-pregn-4-ene-21,17-carbolactone; and 15(3, 16(3-methylene-la, 7a-dimethylthio-3-oxo-17a-pregn-4-ene-21,17-Carbolactone.
Methods to make the compounds of Formula II are described in U.S. Patent No. 4,789,668 to Nickisch et al. which issued 6 December 1988.
Yet another family of non-epoxy-steroidal compounds of interest is defined by a structure of Formula III:

.R
wherein R is lower alkyl, with preferred lower alkyl groups being methyl, ethyl, propyl and butyl. Specific compounds of interest include:
3(3,21-dihydroxy-170c-pregna-5,15-dime-17-carboxylic acid 'y-lactone;
3(3,21-dihydroxy-170(-pregna-5,15-diene-17-carboxylic acid ~r-lactone 3-acetate;
3~3,21-dihydroxy-17a-pregn-5-ene-17-carboxylic acid 'y-lactone;
3(3,21-dihydroxy-l7oc-pregn-5-ene-17-carboxylic acid 'y-lactone 3-acetate;
21-hydroxy-3-oxo-l7oc-pregn-4-ene-17-carboxylic acid 'y-lactone ;
21-hydroxy-3-oxo-l7oc-pregna-4,6-dime-17-carboxylic acid y-lactone;
21-hydroxy-3-oxo-l7oc-pregna-1,4-dime-17-carboxylic acid y-lactone;
70(-acylthio-21-hydroxy-3-oxo-l7oc-pregn-4-ene-17-carboxylic acid ~lactone; and 70c-acetylthio-21-hydroxy-3-oxo-l7oc-pregn-4-ene-17-carboxylic acid 'y-lactone.

Methods to make the compounds of Formula III are described in U.S. Patent No. 3,257,390 to Patchett which issued 21 June 1966.
Still another family of non-epoxy-steroidal compounds of interest is represented by Formula IV:

wherein E' is selected from the group consisting of ethylene, vinylene and (lower alkanoyl)thioethylene radicals, E" is selected from the group consisting of ethylene, vinylene, (lower alkanoyl)thioethylene and (lower alkanoyl)thiopropylene radicals; R is a methyl radical except when E' and E" are ethylene and (lower alkanoyl) thioethylene radicals, respectively, in which case R is selected from the group consisting of hydrogen and methyl radicals; and the selection of E' and E" is such that at least one (lower alkanoyl)thio radical is present.

A preferred family of non-epoxy-steroidal compounds within Formula IV is represented by Formula V:
~o lower (V) A more preferred'compound of Formula V is 1-acetylthio-17a-(2-carboxyethyl)-17(3-hydroxy-androst-4-en-3-one lactone.
Another preferred family of non-epoxy-steroidal compounds within Formula IV is represented by Formula VI:
~o (VI) lower alkyl More preferred compounds within Formula VI include the following:
7oc-acetylthio-17a- (2-carboxyethyl) -17(3-hydroxy-androst-4-en-3-one lactone;
7(3-acetylthio-l7oc- (2-carboxyethyl) -17(3-hydroxy-androst-4-en-3-one lactone;

loc, 7oc-diacetylthio-170c- (2-carboxyethyl) -17(3-hydroxy-androsta-4,6-dien-3-one lactone;~
7oc-acetylthio-17a- (2-carboxyethyl) -17(3-hydroxy-androsta-1,4-dien-3-one lactone;
5 7a-acetylthio-l7oc- (2-carboxyethyl) -17(3-hydroxy-19-norandrost-4-en-3-one lactone; and 7a-acetylthio-l7oc- (2-carboxyethyl) -17(3-hydroxy-6o~-methylandrost-4-en-3-one lactone;
6' 10 In Formulae IV-VI, the term "alkyl" is intended to embrace linear and branched alkyl radicals containing one to about eight carbons. The term "(lower alkanoyl)thio" embraces radicals of the formula lower II
alkyl -~-s .
Of particular interest is the compound spironolactone having the following structure and formal name:
"spironolactone": 17-hydroxy-70~-mercapto-3-oxo-170~-pregn-4-ene-21-carboxylic acid y-lactone acetate.
Methods to make compounds of Formulae IV-VI are described in U.S. Patent No. 3,013,012 to Cella et al.
which issued 12 December 1961. Spironolactone is sold by G.D. Searle & Co., Skokie, Illinois, under the Jl: V l:rig trademark "ALDACTONE", in tablet dosage form at doses of 25 mg, 50 mg and 100 mg per tablet.
Another family of steroidal aldosterone antagonists is exemplified by drospirenone, [6R-(6alpha,7alpha,8beta,9alpha,lObeta,l3beta,l4alpha,l5alph a,l6alpha, l7beta)]-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hex adecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17, 2' (5'H) -furan] -3, 5' (2H) -dione, CAS registration number 67392-87-4. Methods to make and use drospirenone are described in patent GB 1550568 1979, priority DE
2652761 1976.
Definitions The term "treatment" or "treating" includes the administration, to a person in need, of an amount of an aldosterone antagonist and NSAID combination that will inhibit or reverse development of a pathological cardiovascular condition.
The term "prevention" or "preventing" includes either preventing the onset of clinically evident cardiovascular disorders altogether or preventing the onset of a preclinically evident stage of cardiovascular disorder in individuals. This includes prophylactic treatment of those at risk of developing a cardiovascular disorder.
The phrase "therapeutically-effective" is intended to qualify the amount of the two agents given in combination which will achieve the goal of improvement in disorder severity and the frequency of incidence, while avoiding adverse side effects.

The term "subject" for purposes of treatment includes any human or animal subject (preferably mammalian and including, but not limited to, domesticated animals such as those from the bovine, porcine, ovine or equine families, and companion animals such as those from the canine and feline family), susceptible to or suffering from a cardiovascular disorders, and preferably is a human subject. The subject, for example, may be at risk due to diet, exposure to bacterial or viral infection, having common markers present, being genetically predisposed to the cardiovascular disorders, and the like.
The terms "aldosterone antagonist" and "aldosterone receptor antagonist" include a compound that inhibits the binding of aldosterone to mineralocorticoid receptors thereby blocking the biological effects of aldosterone.
The terms "non-steroidal anti-inflammatory drug'' or "NSAID" include a compound whose structure lacks a steroid ring and prevents, reduces or inhibits an inflammatory response in a tissue or organ.
The term "pro-inflammmatory" characterizes molecules produced in the body to induce, activate or enhance an inflammatory response in a tissue or organ.
The term "hydrido" denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical. Where used, either alone or within other terms such as "haloalkyl", "alkylsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More~preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tart-butyl, pentyl, iso-amyl, hexyl and the like. The term "alkenyl" embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The term "alkynyl" denotes linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms.
Examples of such radicals include propargyl, butynyl, and the like. The terms "alkenyl", "lower alkenyl", embrace radicals having "cis" and "traps" orientations, or alternatively, "E" and "Z" orientations. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl"

embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl. The term "halo"
means halogens such as fluorine, chlorine, bromina or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkyloxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term 5 "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to 10 provide haloalkoxy radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals.
Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, 15 fluoroethoxy and fluoropropoxy. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such 20 as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, 25 aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, aryl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl. The term "heterocyclyl" embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-30 shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms (e. g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etC.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e. g. morpholinyl, etC.);
saturated 3 to 6-membered heteromonocycliC group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e. g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyClyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. The term "heteroaryl" embraces unsaturated heterocyclyl radicals. Examples of unsaturated heterocyclyl radicals, also termed "heteroaryl" radicals include unsaturated 3 to 6 membered heteromonocycliC group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e. g. 1H-tetrazolyl, 2H-tetrazolyl, etC.), etc.;
unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e. g., tetrazolo[1,5-b]pyridazinyl, etC.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.;
unsaturated 3 to 6-membered heteromonocycliC group containing a sulfur atom, for example, thienyl, etc.;
unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e. g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e. g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to.6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e. g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e. g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term also embraces radicals where heterocyclyl radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclyl group" may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term "alkylthioalkyl"
embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl radicals are "lower alkylthioalkyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl. The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent -S(=O)- radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl"
radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -S02-. "Alkylsulfonyl"
embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl"
radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote NH202S-. The term "aryl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such lower alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes -(C=O)-. The term "aroyl" embraces aryl radicals with a carbonyl radical as defined above.
Examples of aroyl include benzoyl, naphthoyl, and the like and the aryl in said aroyl may be additionally substituted. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes -C02H. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower alkoxycarbonyl" radicals with alkyl porions having 1 to 6 carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The terms "alkylcarbonyl", "arylcarbonyl" and "aralkylcarbonyl"
include radicals having alkyl, aryl and aralkyl radicals, as defined above, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl. The term "aralkyl"
embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable. The term "heterocyclylalkyl" embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkoxyalkyl" embraces aralkoxy radicals attached through an oxygen atom to an alkyl radical. The term "aralkylthio" embraces aralkyl 5 radicals attached to a sulfur atom. The term "aralkylthioalkyl" embraces aralkylthio radicals attached through a sulfur atom to an alkyl radical. The term "aminoalkyl" embraces alkyl radicals substituted with one or more amino radicals. More preferred are 10 "lower aminoalkyl" radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like. The term "alkylamino" denotes amino groups which have been substituted with one or two alkyl radicals. Preferred are "lower N-alkylamino" radicals having alkyl portions 15 having 1 to 6 carbon atoms. Suitable lower alkylamino may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals, 20 such as N-phenylamino. The "arylamino" radicals may be further substituted on the aryl ring portion of the radical. The term "aralkylamino" embraces aralkyl radicals attached through an amino nitrogen atom to other radicals. The terms "N-arylaminoalkyl" and "N-25 aryl-N-alkyl-aminoalkyl" denote amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-30 methylaminomethyl. The term "aminocarbonyl" denotes an amide group of the formula -C(=O)NH2. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" "N,N-dialkylaminocarbonyl" radicals.
More preferred are "lower N-alkylaminocarbonyl" "lower N,N-dialkylaminocarbonyl" radicals with lower alkyl portions as defined above. The term "alkylaminoalkyl"
embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical. The term "aryloxyalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a divalent oxygen atom. The term "arylthioalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a divalent sulfur atom.
The compounds utilized in the methods of the present invention may be present in the form of free bases or pharmaceutically acceptable acid addition salts thereof. The term "pharmaceutically-acceptable salts"
embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, malefic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, b-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-diben~ylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.
COMBINATIONS
The present invention is further directed to combinations comprising an aldosterone antagonist and a NSAID. In one embodiment, the combination is a pharmaceutical composition comprising an aldosterone antagonist and a NSAID. One illustrative, nonlimiting example is a pharmaceutical composition comprising eplerenone and diclofenac.
PHARMACEUTICAL COMPOSITIONS
The present invention comprises a pharmaceutical composition for the prevention or treatment of cardiovascular disorders, comprising a therapeutically-effective amount of an aldosterone antagonist and NSAID
combination in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route known to those skilled in the art, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly, intraperitoneally, intranasally, intrabronchially, subcutaneously, intramuscularly or topically (including aerosol).
Administration of aldosterone antagonist and NSAID combination may take place sequentially in separate formulations, or may be accomplished by simultaneous administration in a single formulation or separate formulations. Administration may be accomplished by oral route, or by intravenous, intramuscular or subcutaneous injections. The formulation may be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, or a binder such as gelatin or hydroxypropyl-methyl cellulose, together with one or more of a lubricant, preservative, surface-active or dispersing agent.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. These may contain, for example, an amount of each active ingredient from about 1 mg to about 1000 mg, or about 5 mg to about 500 mg, or about mg to about 250 mg, or about 25 mg to about 150 mg. A
suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.01 to 30 mg/kg 5 body weight, particularly from about 1 to 15 mg/kg body weight, may be appropriate.
The active ingredients may also be administered by injection as a composition wherein, for 10 example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose of each active component is from about 0.01 to 15 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 10 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 15 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 15 mg per kilogram of body weight.
Most preferred is a dosage in a range from about 1 to about 10 mg per kilogram of body weight per day. A
suitable dose can be administered, in multiple sub-doses per day. These sub-doses may be administered in unit dosage forms.
In one embodiment the aldosterone receptor antagonist may be present in an amount in a range from about 1 mg to about 200 mg, and the NSAID may be present in an amount in a range from about 1 mg to about 800 mg, which represents aldosterone antagonist-to-NSAID ratios ranging from about 200:1 to about 1:800.
In another embodiment, the aldosterone receptor antagonist may be present in an amount in a range from about 5 mg to about 400 mg, and the NSAID may be present in an amount in a range from about 1 mg to about 200 mg, which represents aldosterone antagonist-to-NSAID ratios ranging from about 400:1 to about 1:40.
In another embodiment, the aldosterone 5 receptor antagonist may be present in an amount in a range from about 10 mg to about 200 mg, and the NSAID
may be present in an amount in a range from about 5 mg to about 100 mg, which represents aldosterone antagonist-to-NSAID ratios ranging from about 40:1 to 10 about 1:10.
In another embodiment, the aldosterone receptor antagonist may be present in an amount in a range from about 20 mg to about 100 mg, and NSAID may be 15 present in an amount in a range from about 10 mg to about 80 mg, which represents aldosterone antagonist-to-NSAID ratios ranging from about 10:1 to about 1:4.
The NSAID dose administered to the subject or 20 contained in the pharmaceutical composition can vary and generally wil l depend on the particular NSAID used, inherent potency, bioavailability and metabolic lability of the composition and whethter it has been formulated for immediate release or extended release.
25 Non-limiting examples of dose ranges for specific NSAIDs are listed below:
Component COMPOUND ILLUSTRATIVE ILLUSTRATIVE
Number DOSAGE FORM DOSE

N-1 acetaminophen ca sule/oral 2.5 mg - 650 m N-2 benoxaprofen N-3 ca rofen N-4 diclofenac tablet/oral; 0.2 mg - 75 mg gel; 3%
solution 0.1 N-5 diflunisal tabletloral 250 mg - 500 m N-6 etodolac ca sule/oral 400 mg - 600 m N-7 feno rofen ca sule/oral 200 m - 400 mg N-8 flurbiprofen capsule/oral; 50 mg - 100 mg solution 0.03%

N-9 ibuprofen tablet/oral; 7.5 mg - 800 sus ension; mg 40 mg/ml - 100 mg/5 ml N-10 indomethacin capsule/oral; 25 mg - 75 mg suppository; 25 mg- 50 mg injectable/injection1 mg N-11 ketoprofen capsule/oral 25 mg- 200 mg N-12 ketorolac N-13 meclofenamate N-14 mefenamic acidcapsule/oral 250 mg N-15 nabumetone tablet/oral 500 mg - 750 mg N-16 naproxen suspension 25 mg tablet/oral 250 m - 500 mg N-17 oxa rozin tablet/oral 600 m N-18 ox henbutazone N-19 phenylbutazone N-20 iroxicam ca sule/oral 10 m - 20 m N-21 sulindac tablet/oral 150 mg-200 mg N-22 su rofen solution 1%

N-23 tenidap N-24 tolinetin tablet/oral 200 mg - 600 mg N-25 zome irac N-26 aspirin tablet/oral ~ 0.19 mg - 770 mg One of ordinary skill in the art will be capable of using these dose ranges as a suitable starting point to administer this therapy, after which the dose may be titrated up or down, depending on the response of the subject being treated.
The dosage regimen for treating a disease condition with the combination therapy of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular compound employed, and thus may vary widely.
Below, non-limiting examples of combinations of the present invention are listed wherein the combination comprises a first amount of an aldosterone receptor antgonist and a second amount of a NSAID
wherein the first amount and second amount together comprise a therapeutically-effective amount of an aldosterone receptor antagonist and a NSAID:

1 Eplerenone N 1 2 Eplerenone N-2 3 Eplerenone N-3 4 Eplerenone N-4 Eplerenone N-5 Eplerenone N-6 7 Eplerenone N-7 8 Eplerenone N-8 Eplerenone N-g Eplerenone N-10 11 Eplerenone N-11 12 Eplerenone N-12 13 Eplerenone N-13 14 Eplerenone N-14 Eplerenone N-15 Eplerenone N-16 Eplerenone N-17 18 Eplerenone N-18 19 Eplerenone N-19 Eplerenone N-20 21 Eplerenone N-21 22 Eplerenone N-22 23 Eplerenone N-23 24 Eplerenone N-24 Eplerenone N-25 26 Eplerenone N-26 27 Spironolactone N-1 28 Spironolactone N-2 29 Spironolactone N-3 Spironolactone N-4 31 Spironolactone N-5 32 Spironolactone N-6 33 Spironolactone N-7 34 Spironolactone N-8 35 Spironolactone N-9 36 Spironolactone N-10 3~ Spironolactone N-11 38 Spironolactone N-12 39 Spironolactone N-13 40 Spironolactone N-14 41 Spironolactone N-15 42 Spironolactone N-16 43 Spironolactone N-17 44 Spironolactone N-18 45 Spironolactone N-19 46 Spironolactone N-20 4~ Spironolactone N-21 48 Spironolactone N-22 49 Spironolactone N-23 50 Spironolactone N-24 51 Spironolactone N-25 52 Spironolactone N-26 For therapeutic purposes, the active components of this combination therapy invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the components may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The components may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, ben~yl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
The present invention further comprises kits that are suitable for use in performing the methods of treatment and/or prophylaxis described above. In one embodiment, the kit contains a first dosage form comprising one or more of the epoxy-steroidal aldosterone antagonists previously identified and a second dosage form comprising a NSAID identified in Table 1 in quantities sufficient to carry out the methods of the present invention. Preferably, the first dosage form and the second dosage form together comprise a therapeutically effective amount of the compounds. In another embodiment, the kit further comprises written instructions stating how the contents of the kit can be used by the subject. The written instructions will be useful, for example, for the subject to obtain a therapeutic effect without inducing unwanted side-effects. In another embodiment the written instructions comprise all or a part of the product label approved by a drug regulatory agency for the kit.

Crystalline Forms of Active Com ounds It is particularly useful to select a form of each active compound that is easily handled, reproducible in 5 form, easily prepared, stable and which is non-hygroscopic. By way of illustration and not limitation, several crystalline forms have been identified for the aldosterone antagonist eplerenone. These include Form H, Form L, various crystalline solvates and amorphous 10 eplerenone. These forms, methods to make these forms and use of these forms in preparing compositions and medicaments, are disclosed in the following publications, incorporated herein by reference:
WO 01/41535 and WO 01/42272.
Subject Populations Certain groups are more prone to disease modulating effects of aldosterone. Members of these groups that are sensitive to aldosterone are typically also salt sensitive, wherein individuals blood pressure generally rises and falls with increased and decreased sodium consumption, respectively. While the present invention is not to be construed as limited in practice to these groups, it is contemplated that certain subject groups may be particularly suited for therapy with an anti-inflammatory dose of an aldosterone blocker of the present invention.
Accordingly, subjects who can benefit from treatment or prophylaxis in accordance with the method of the present invention are human subjects generally exhibiting one or more of the following characteristics:

(a) the average daily intake of sodium chloride by the subject is at least about 4 grams, particularly where this condition is satisfied over any one month interval for at least one or more monthly intervals over a given annual period. The average daily intake of sodium by the subject preferably is at least about 6 grams, more preferably at least about 8 grams, and still more preferably at least about 12 grams.
(b) the subject exhibits an increase in systolic blood pressure and/or diastolic blood pressure of at least about 5%, preferably at least about 7%, and more preferably at least about 100, when daily sodium chloride intake by the subject is increased from less than about 3 g/day to at least about 10 g/day.
(C) the activities ratio of plasma aldosterone (ng/dL) to plasma renin (ng/ml/hr) in the subject is greater than about 30, preferably greater than about 40, more preferably greater than about 50; and still more preferably greater than about 60.
(d) the subject has low plasma renin levels; for example, the morning plasma renin activity in the subject is less than about 1.0 ng/dL/hr, and/or the active renin value in the subject is less than about 15 pg/mL .
(e) the subject suffers from or is susceptible to elevated systolic and/or diastolic blood pressure. In general, the systolic blood pressure (measured, for example, by seated cuff mercury sphygmomanometer) of the subject is at least about 130 mm Hg, preferably at least about 140 mm Hg, and more preferably at least about about 150 mm Hg, and the diastolic blood pressure (measured, for example, by seated cuff mercury sphygmomanometer) of the subject is at least about 85 mm Hg, preferably at least about 90 mm Hg, and more preferably at least about 100 mm Hg.
(f) the urinary sodium to potassium ratio (mmol/mmol) of the subject is less than about 6, preferably less than about 5.5, more preferably less than about 5, and still more preferably less than about 4.5.
(g) the urinary sodium level of the subject is at least 60 mmol per day, particularly where this condition is satisfied over any one month interval for at least one or more monthly intervals over a given annual period. The urinary sodium level of the subject preferably is at least about 100 mmol per day, more preferably at least about 150 mmol per day, and still more preferably 200 mmol per day.
(h) the plasma concentration of one or more endothelins, particularly plasma immunoreactive ET-1, in the subject is elevated. Plasma concentration of ET-1 preferably is greater than about 2.0 pmol/L, more preferably greater than about 4.0 pmol/L, and still more preferably greater than about 8.0 pmol/L.
(I) the subject has blood pressure that is substantially refractory to treatment with an ACE
inhibitor; particularly a subject whose blood pressure is lowered less than about 8 mm Hg, preferably less than 5 mm Hg, and more preferably less than 3 mm Hg, in response to 10 mg/day enalapril compared to the blood pressure of the subject on no antihypertensive therapy.

(j) the subject has blood volume-expanded hypertension or blood volume-expanded borderline hypertenision, that is, hypertension wherein increased blood volume as a result of increased sodium retension contributes to blood pressure.
(k) the subject is a non-modulating individual, that is, the individual demonstrates a blunted positive response in renal blood flow rate and/or in adrenal production of aldosterone to an elevation in sodium intake or to angiotensin II administration, particularly when the response is less than the response of individuals sampled from the general geographical population (for example, individuals sampled from the subject's country of origin or from a country of which the subject is a resident), preferably when the response is less than 40% of the mean of the population, more preferably less than 30%, and more preferably still less than 200.
(I) the subject has or is susceptible to renal dysfunction, particularly renal dysfunction selected from one or more members of the group consisting of reduced glomerular filtration rate, microalbuminuria, and proteinuria.
(m) the subject has or is susceptible to cardiovascular disease, particularly cardiovascular disease selected from one or more members of the group consisting of heart failure, left ventricular diastolic dysfunction, hypertrophic cardiomyopathy, and diastolic heart failure.
(r1) the subject has or is susceptible to liver disease, particularly liver cirrhosis.

(o) the subject has or is susceptible to edema, particularly edema selected from one or more members of the group consisting of peripheral tissue edema, hepatic or splenic congestion, liver ascites, and respiratory or lung congestion.
(p) the subject has or is susceptible to insulin resistance, particularly Type I or Type II diabetes mellitus, and/or glucose sensitivity.
(q) the subj ect is at least 55 years of age, preferably at least about 60 years of age, and more preferably at least about 65 years of age.
(r) the subject is, in whole or in part, a member of at least one ethnic group selected from the Asian (particularly from the Japanese) ethnic group, the American Indian ethnic group, and the Black ethnic group.
(S) the subject has one or more genetic markers associated with salt sensitivity.
(t) the subject is obese, preferably with greater than 25% body fat, more preferably with greater than 30%
body fat, and even more preferably with greater than 350 body fat.
(U) the subj ect has one or more 1St, 2nd or 3ra degree relatives who are or were salt sensitive, wherein 1St degree relatives means parents or relatives sharing one or more of the same parents, 2na degree relatives means grandparents and relatives sharing one or more of the same grandparents, and 3ra degree relatives means great-grandparents and relatives sharing one or more of the same great-grandparents. Preferably, such individuals have four or more salt sensitive 1St, 2nd, or 3rd degree relatives; more preferably, eight or more such relatives; even more preferably, 16 or more such relatives; and even more preferably still, 32 or more 5 such relatives.
Unless otherwise indicated to the contrary, the values listed above preferably represent an average value, more preferably a daily average value based on at least two measurements.
10 Preferably, the subject in need of treatment satisfies at least two or more of the above-characteristics, or at least three or more of the above-characteristics, or at least four or more of the above-characteristics.
Biological Evaluation Human cardiovascular disorders are complex conditions, often initiated by vascular hypertension or a myocardial infarction (MI). In order to determine the probable effectiveness of a therapy for cardiovascular disorders, it is important to determine the potency of components in several assays. Accordingly, in Assay "A", the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) was determined in a hypertensive rat model with vascular inflammation, using angiotensin II infusion. In Assay "B" a study is described evaluating the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) in a rat model using aldosterone infusion to produce hypertension with vascular inflammation. In Assay "C" a further study is described evaluating the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) in a rat model using aldosterone infusion to produce hypertension with vascular inflammation.
In addition, clinical trials can be used to evaluate aldosterone antagonist therapy in humans.
Numerous examples of such therapeutic tests have been published, including those of the RAZES 003 study described in American Journal of Cardiology 78, 902-907 (1996) or the RAZES 004 study described in New England Journal of Medicine 341, 709-717 (1999).
Assay A: In Vivo Angiotensin II Infusion Model Protocol:
Methods:
~ Male Wistar rats (n=50, 10/group; BW=200 g) ~ 1% NaCl to drink ~ Experimental groups 1. Control 2. Angiotensin II (25 ng/min, sc via alzet minipump) 3. Angiotensin II (25 ng/min, sc) + eplerenone 100 mpk 4. Angiotensin II (25 ng/min, sc) + adrenalectomy +
dexamethasone (12 ~,g/kg/d, sc) 5. Angiotensin II (25 ng/min, sc) + adrenalectomy +
dexamethasone (12 ~.g/kg/d, sc) + aldosterone (40 mg/kg/d, sc via alzet minipump) ~ SBP measured by tail-cuff every week ~ 24-hours food and fluid intake and urine output measured every day ~ Urine samples collected every day for determination S of urinary electrolytes.
~ Sacrifice by exanguination after 4 weeks. Blood was be collected in dry tubes for determination of serum electrolytes and in EDTA-containing tubes for measurement of aldosterone and corticosterone levels ~ Hearts were stained with hematoxylin&eosin and have been analyzed for determination of morphologic abnormalities (i.e. necrosis, vascular injury).
Results Blood pressure. Systolic blood pressure increased in all animals receiving angiotensin II infusion. Neither eplerenone nor adrenalectomy reduced blood pressure when compared to animals receiving vehicle. Aldosterone infusion increased blood pressure in angiotensin II/salt, adrenalectomized rats. Fig. 1 demonstrates this increase in systolic blood pressure.
Electrolyte excretion. The ratio between daily urinary Na+ excretion and urinary K+ excretion (U Na+/K+ ratio) was used as an index for natriuresis. Urinary Na+/K+
ratio was similar in all groups before the start of the treatments, and increased similarly in all animals upon initiation of the high salt diet. Urinary Na+/K+ ratio was not unchanged in animals receiving angiotensin II
infusion until day 17 when it was significantly increased in these animals with respect to the vehicle-infused rats. A similar effect occurred in angiotensin II-infused animals receiving eplerenone, which demonstrated increases in urinary Na+/K+ ratio from day 14 of infusion. However, at no time-point did eplerenone-treated rats demonstrate higher urinary Na+/K+ ratio than angiotensin II-infused rats treated with vehicle. In fact, a significant difference was only observed at day 21, when angiotensin II-infused, vehicle treated rats demonstrated higher urinary Na+/K+
ratio than eplerenone-treated animals indicating that, under these experimental conditions eplerenone did not produce a significant diuretic or natriuretic effect.
Adrenalectomized animals with or without aldosterone infusion always demonstrated higher urinary Na+/K+ ratio than the adrenal-intact animals.
Myocardial injury. Seven out of the ten angiotensin II/salt-treated animals developed vascular inflammatory changes in the coronary arteries. These changes were characterized by leukocyte infiltration of the perivascular space, mainly by macrophages. Fibrinoid necrosis of the media was also observed in some arteries. In some cases, when the lesions were extensive there was cardiomyocyte necrosis associated in the surrounding myocardium. P,arenchymal hemorrhages were observed in these cases, consistent with findings of myocardial necrosis. These vascular inflammatory lesions were observed in only one of the ten angiotensin II~-infused animals receiving eplerenone, despite the fact that these animals were as hypertensive as the vehicle-treated angiotensin II-infused rats. (See Fig.
2). Similarly, adrenalectomy prevented the vascular inflammatory lesions in the heart. However, aldosterone replacement restored the severe coronary and myocardial inflammation and injury observed in angiotensin-II
infused, adrenal-intact, vehicle-treated rats.
Immunostaining of the hearts from angiotensin II-infused rats with a cyclooxgenase-2 specific antibody identified the presence of this enzyme in areas of inflammation around the arteries, mainly in monocyte/macrophages.
Cycloxygenase-2 staining was also observed in the vascular smooth muscle cells of the media of coronary arteries, even when there was no evidence of morphologic alterations or inflammatory aggregates in the perivascular space (Fig. 4). Eplerenone treatment, as well as adrenalectomy markedly reduced and in most cases completely prevented the expression of cycloxygenase-2 in the hearts from angiotensin II-infused rats (See Figs. 3 and 5). Replacement of aldosterone in angiotensin-II, adrenalectomized rats restored the presence of cycloxygenase-2 in coronary arteries.
Osteopontin (also known as early T-cell activation-1, Eta-1) is a secreted glycoprotein with pro-inflammatory characteristics that mediates chemoattraction, activation and migration of monocytes.
Immunostaining of the hearts from angiotensin II-infused, saline-drinking rats with an osteopontin-specific antibody identified the presence of osteopontin in the media of coronary arteries. Both eplerenone treatment and adrenalectomy prevented osteopontin expression in the hearts of angiotensin II-infused, saline-drinking rats (Figs. 6 and 7). Aldosterone replacement restored osteopontin expression in adrenalectomized animals.

Assay B: In Vivo Aldosterone Infusion Model Protocol 2:
5 Methods:
~ Male Sprague Dawley rats (n=39; BW=250 g) ~ 1% NaCl to drink ~ Uni-nephrectomy performed during implantation of mini-pumps 10 ~ Experimental groups 1. Con trol 2. Aldosterone (0.75 mg/hr, sc via alzet minipump) 2. Aldosterone (0.75 mg/hr, sc tria alzet minipump) 15 + eplerenone 100 mpk, p.o 1. Aldosterone (0.75 mg/hr, sc via alzet minipump) + 0.6o KCl in the drinking fluid ~ Groups l, 2 and 3 received only 0.3% KCl in the 20 drinking solution ~ SBP measured by radio-telemetry probes inserted in the abdominal aorta ~ Sacrifice after 4 weeks.
-~ Hearts were harvested and divided by half through a 25 transverse section at the mid-ventricles: The upper half was stored into formalin. The bottom part was snap-frozen in liquid nitrogen for biochemical analysis.
~ Hearts were stained with hematoxylin & eosin and the 30 collagen specific dye picro-sirius red and were analyzed for determination of interstitial collagen volume fraction and morphologic abnormalities (i.e.
necrosis, vascular injury).
~ Hydroxyproline concentration was measured in the frozen hearts.
~ Determination of osteopontin and COX-2 was performed by quantitative RT-PCR (Taqman). Osteopontin was also identified in the heart by immunohistochemistry.
Results Blood pressure. Systolic blood pressure increased in all animals receiving aldosterone infusion. Eplerenone treatment significantly reduced, but did not normalize blood pressure. Fig. 21 shows these results graphically.
Myocardial injury. Saline-drinking, uni-nephrectomized rats did not have myocardial injury. Determination of interstitial collagen by histologic determination of interstitial collagen volume fraction or by biochemical determination of hydroxyproline concentration evidenced the absence of myocardial fibrosis in animals receiving aldosterone/salt treatment. However, examination of the hematoxilin-eosin-stained hearts from aldosterone/salt-treated rats evidenced severe vascular inflammatory lesions. These lesions were identical to those described in protocol 1. Administration of eplerenone completely prevented the vascular inflammatory changes in aldosterone-infused, saline-drinking, uni-nephrectomized rats (Fig. 10), even though it did not normalize blood pressure. Elevations of dietary potassium did not have significant effects in the development of aldosterone-induced injury, as these animals demonstrated similar levels of injury as the aldosterone/salt treated rats receiving vehicle.
Serum osteopontin levels were determined at 28 days, and measured for each group (NaCl 1o drinking rats, NaCl 1o drinking rats with aldosterone, and NaCl 1% drinking rats with aldosterone and eplerenone). Fig.
23 shows the marked decrease in circulating osteopontin levels in the eplerenone treated rats.
Osteopontin immunostaining was also performed in the hearts from these animals. Osteopontin was not detected in saline-drinking, uninephrectomized animals receiving no aldosterone. However, osteopontin was clearly identified in the media of coronary arteries in animals receiving aldosterone infusion. Eplerenone treatment, prevented the expression of osteopontin in the hearts from aldosterone-infused rats (Figs. 8 and 18). Increases in dietary potassium did not reduce osteopontin expression. Determination of osteopontin mRNA by quantitative RT-PCR, demonstrated a marked (7-fold) upregulatoin of this Cytokine in the hearts of aldosterone/salt-treated rats receiving vehicle (relative mRNA expression: 1.7~.2 vs 12.25~1.7, P<.0001). This effect was prevented by eplerenone (relative mRNA expression: 2.5~.6, P<.0001 vs aldosterone/salt+vehicle group). Consistent with a role for cycloxygenase-2 in the development aldosterone-induced vascular inflammation in the heart, COX-2 mRNA
expression was 3-fold increased in rats with aldosterone/salt+vehicle treatment (relative mRNA
expression: 1.2~.12 vs 3.7~.46, P<.0001). Similar to the effects on osteopontin expression, eplerenone prevented the increase in COX-2 expression in aldosterone/salt-treated rats (relative mRNA expression:
1.8~.36, P<.01 vs aldosterone/salt+vehicle group, see Figs. 9 and 17). In like fashion, MCP-1 expression and IL-6 expression was attenuated by eplerenone treatment (Fig. 24).
The above data suggest that aldosterone mediates a vascular inflammatory phenotype in the heart of hypertensive rats. This phenotype is associated with up-regulation of the cytokine osteopontin and the enzyme cycloxygenase-2 in vascular smooth muscle cells in the arterial media, which may mediate the perivascular inflammation observed and the consequent ischemic/necrotic injury of coronary arteries and myocardium. Without wishing to be bound by any theory, it is believed that this is the mechanism that mediates the vascular alterations observed in diseases such as heart failure, coronary artery disease, auto-immune or viral myocarditis, periateritis nodosa, stroke, and nephrosclerosis. Fig. 11 reveals that osteopontin and cyclooxygensase-2 are expressed in similar regions of the coronary arterial wall. While~theory plays no part in the instant invention, Fig. 12 shows a proposed mechanism for this model. In these examples, eplerenone treatment prevented the vascular inflammation in the heart to an extent similar to that of adrenalectomy, as demonstrated in protocol #1. The effects of eplerenone were largely independent of major reductions in systolic blood pressure as demonstrated in protocol #1. The lack of a diuretic or natriuretic effect of eplerenone in angiotensin II/salt hypertensive rats suggests that the protective effects of the selective aldosterone antagonist were also independent of its potential effects on epithelial tissues. In addition, the fact that an elevated dietary potassium failed to mimic the effects of eplerenone, argue against the possibility that eplerenone provides benefit through its potassium-sparing properties. Thus, we propose that aldosterone may have direct deleterious effects in the coronary vasculature unrelated to the effects of this hormone in electrolyte homeostasis in epithelial tissues or its effects on blood pressure. Administration of eplerenone to humans could provide benefit by its anti-inflammatory effects in vascularized organs, including but not limited to heart, kidney, and brain, as suggested by the present experiment.
Assay C: Further In Vivo Aldosterone Infusion Study The procedure of Assay B was expanded upon in a further study. Uninephrectomized, Sprague-Dawley rats were given 1%NaCl-0.3%KCl to drink and one of the following treatments: vehicle; aldosterone infusion; or aldosterone infusion in combination with eplerenone (100 mg/kg/day). Aldosterone/salt treatment induced severe hypertension in rats after 30 days, which was significantly reduced by eplerenone. Myocardial tissue from animals in each treatment group was examined after 7, 14, or 30 days of treatment. Histopathologic analysis revealed vascular inflammatory lesions starting at 14 days that extended to surrounding myocardium and resulted in focal ischemic/necrotic changes. Lesions were preceded by the expression and progressive upregulation of proinflammatory molecules. Upregulation of proinflammatory molecules and associated vascular and myocardial damage were markedly attenuated by eplerenone treatment. These data demonstrate that eplerenone is effective in reducing blood pressure and providing end-organ protection against aldosterone-induced vascular 5 inflammatory damage in the heart.
Animals Male Sprague-Dawley rats, weighing 230 to 250 g, (Harlan Sprague-Dawley Industries, Indianapolis, IN) were housed 10 in a room 12-hours light/12-hours dark daily cycle at an ambient temperature of 22~1°C (n=96). Animals were allowed one week to adjust after arrival and had free access to TEKLAD 22/5 rodent diet (Harlan TEKLAD, Madison, WI) and tap water until the initiation of the 15 experiment.
Experimental Protocol Prior to surgery the animals were individually weighed and placed in one of the following groups: (I) high salt 20 control (vehicle/normal chow/1% NaCl & 0.3o KCl drinking water, n=31 for 3 time point groups), (II) aldosterone control (aldosterone/normal chow/1o NaCl & 0.3% KCl drinking water, n=28 for 3 time point groups), (III) 100 mg/kg/day eplerenone (aldosterone/eplerenone chow/1%NaCl 25 & 0.3o KCl drinking water, n=30 for 3 time points).
Potassium chloride supplementation was added to the saline solution in order to prevent the potential hypokalemia associated with aldosterone excess.
Treatment 30 At the time of the surgery, an Alzet 2002 osmotic minipump (Alza Corp., Palo Alto, CA) containing either vehicle (9% ethanol/87% propylene glycol/4% dH20) or 1.0 mg/mL d-aldosterone (Sigma Chemical, St. Louis, MO) was inserted subcutaneously at the nape of the neck.
Aldosterone was administered at a dose of 0.75 Og/hour.
Eplerenone was incorporated into TEKLAD 22/5 rodent diet (Harlan TEKLAD, Madison, WI) at a concentration of lmg/g of chow (calculated to deliver 100 mg/kg/day). Previous analytical work has demonstrated the stability of eplerenone in this diet, as well as the homogeneity obtained after preparation. Animals were sacrificed from each group (n=8-13) after 7, 14, or 30 days of treatment.
Surgical procedure Animals to be sacrificed after 7 or 14 days of treatment were uninephrectomized and implanted with an Alzet minipump. Animals treated for 30 days were uninephrectomized, fitted for Alzet minipumps, and implanted with radio telemetry units (model# TA11PA-C40, Data Sciences Inc., St. Paul, MN) according to the following procedure. Animals were anesthetized with 50 isoflurane (SOLVAY Animal Health Inc., Mendota Heights, MN), which was delivered in 02 using a VMS anesthesia instrument (Matrix Medical, Inc., Orchard Park, NY).
Anesthesia was maintained with 1-2% isoflurane throughout the surgical procedure. The surgery site was clipped, scrubbed with nolvasan, and sprayed with betadine. A rostral-caudal incision was made through the skin from the base of the rib cage to the pubic region using a #11 scalpel blade. A second incision was made through the muscles of the abdominal wall to expose the peritoneal cavity. The urethra, renal artery and vein of the left kidney were isolated, tied off with 4-0 silk, and the kidney excised and discarded. Organs were carefully displaced with tissue retractors in order to expose the abdominal aorta. A 1.5 cm segment just rostral to the bifurcation of the abdominal aorta into the iliac arteries was cleared of excessive connective tissue and 4-0 silk was used to make an anchor adjacent to the aorta. A microvascular clip was then placed at both ends of the cleaned region to stop excessive blood flow. Using a bent, 21 gauge needle, the abdominal aorta was penetrated. The cannula of the radio telemetry unit was inserted and stabilized in the aorta using the 4-0 silk anchor. Organs were repositioned and the telemetry unit was placed over the organs. Using a non-interrupted suture pattern with 4-0 silk, the abdominal wall was closed, and the skin was subsequently closed using a 4-0 silk in an interrupted suture pattern. Animals were injected around the sutures with 100 ~,L of the anesthetic Marcaine HCl (Sanofi Winthrop Pharmaceuticals, New York, NY) and given an injection (i.m.) of the antibiotic Mandol (Eli Lilly & Co., Indianapolis, IN). Post-operative care included monitoring the animals on a heating pad during recovery from anesthesia until sternal recumbency was reestablished. Animals were monitored daily for signs of distress and infection at the surgical site. Animals displaying continued discomfort after surgery were treated with 0.1-0.5 mg/kg, s.c. Buphrenorphine (Rickett & Colman Pharmaceuticals, Inc. Richmond, VA).
Animals were then placed on tap water and TEKLAD 22/5 rodent diet (Harlan TEKLAD, Madison, WI).

Blood Pressure Analysis Radiotelemetrized arterial blood pressure was calculated with the DATAQUEST A.R.T Version 1.1-Gold software (Data Sciences International, St. Paul, MN). Data points were collected over a 24 hour period with the collection rate set for a 10 second reading every 5 min for each animal.
The 24 hour period used was from 6:00 a.m. to 6:00 a.m.
Sacri fi ce At the cessation of each experimental time point, the animals were anesthetized with pentobarbital (65 mg/kg i.p., Sigma Chemical, St. Louis MO) and weighed with a Mettler PM6000 balance (Mettler-Toledo, Inc., Hightstown, NJ). The abdominal cavity was opened to expose the abdominal aorta. A 16-gauge needle was inserted into the abdominal aorta and the animal was exsanguinated into a l2cc syringe. The blood sample was transferred immediately into glass serum collection tubes (Terumo Medical Corp., Elkton, MD) for drug level analysis. The samples were placed on wet ice until sample collection was complete and centrifuged for 15 min at 3000 rev/min at 4°C.
Following exsanguination, hearts and kidneys were isolated, removed, rinsed in cold phosphate-buffered saline, and blotted dry. Kidneys were immediately bifurcated through the long axis with a razor blade and placed in loo neutral buffered formalin (NBF, Richard-Allen Scientific, Kalamazoo, MI). For the hearts, the right ventricle (RV) was cut away from the left ventricle (LV), both ventricles were weighed using a Mettler AE163 balance (Mettler-Toledo, Inc., Hightstown, NJ), and the RV was placed in 10% NBF. A 2 mm coronal slab of the L~V apex was removed and frozen with dry ice/isopentane for analysis of gene expression and the remaining portion of the LV was placed in 10o NBF for fixation. Final wet trimming was completed after 3-4 days fixation where a second 2 mm coronal slab was removed for hydroxyproline analysis and a third 2mm slab was removed from the equatorial region for histology.
Tissue Processing & Staining The equatorial regions of the heart were routinely processed into paraffin with an automated tissue processor (Hypercenter XP, Shandon/Lipshaw Inc., Pittsburgh, PA) and embedded into fresh paraffin apical side down (Shandon Embedding Center, Shandon/Lipshaw Inc.). Five and 10 um sections were cut from each block of tissue using a Leica RM2035 rotary microtome (Leica Inc., Houston, Texas) and mounted on Superfrost/Plus microscope slides (Fisher Scientific, Pittsburgh, PA).
Ten ,um sections were stained with the collagen specific stain, Picrosirius Red F3BA (Saturated Picric Acid (Sigma Chemical, St. Louis, MO) with 0.10 (w/v) Sirius Red F3BA (C. I. #35780, Pfaltz & Bauer, Inc. VJaterbury, CN) (6). Mounted tissues were hydrated with water.
Slides were subsequently incubated in distilled water with 0.20 (w/v) Phosphomolybdic Acid (Sigma Chemical, St. Louis MO) for 15 min, transferred to 0.10 Picrosirius Red F3BA stain for 110 min, placed in 950 ethanol w/ 1% acetic acid (v/v) for 1 min followed by two, 1-min incubations in 1000 ethanol, and cleared in xylene for 1 min. Slides were coverslipped with #1 cover glass using Permount Histological Mounting Media (Fisher Scientific). Two slides mounted with 5 ~m sections were cut for each animal. One slide was processed for H&E staining and one for Periodic Acid Schiff (PAS) staining. The H&E and PAS were used for pathological scoring of the hearts.

Histopathologic Analysis Semi-quantification of myocardial injury was performed as described previously with minor modifications (7).
Briefly, a scale from 0 to 4 was used to score the level 10 of myocardial injury. A score of 0 represented no damage. A score of 1 represented the presence of vascular and perivascular inflammatory lesions without cardiomyocyte injury. A score of 2 was given when one clear area of myocardial necrosis was observed.
15 Myocardial necrosis was defined as the presence of necrotic changes in cardiomyocytes such as nuclear ' pyknosis or karyolysis, non-contracting marginal wavy fibers and hypereosinophilia of the cytoplasm, or clear evidence of destruction of the cardiomyocyte membrane.
20 When two or more separate areas of necrosis were found (implicating the presence of two different infracted regions), hearts received a score of 3. A score of 4 was assigned to hearts that demonstrated extensive areas of necrosis compromising more than 500 of the left 25 ventricle.
Image Analysis Picrosirius Red F3BA stained slides were used to quantify interstitial collagen with a Videometric 150 30 Image Analysis System (Oncor Inc., Gaitherburg, MD).
Briefly, images were captured using a Nikon E Plan 10/0.25; 160/- Objective (Nikon Inc. Garden City, NY) attached to a Nikon Optiphot microscope (Nikon Inc.). A
Toshiba 3 CCD Color Video Camera (Model#IK-T30T, Toshiba Corp. Japan) relayed the images in RGB format from the microscope to a 386 computer with a V150 video board.
The V150 video board/V150 software application (Oncor Inc.) converted RGB images to HIS (Hue, Intensity, Saturation) format for display and analysis on a Sony Trinitron Color Video Monitor (Model#PVM-1342Q, Sony Corp, Tokyo, Japan) at a magnification of 305x. Once the image was displayed on the image monitor; hue, intensity, and saturation of pixels to be measured were defined by a process called thresholding. The V150 application then measured only pixels which fell into thresholding limits. The system was calibrated with a micrometer scale (EM Sciences, FT. Washington, PA
19034), which allowed data to be expressed in mm2 or Omz. After each measurement, data was automatically saved in ASCII file format and transferred to Microsoft Excel version 7.0 for final summation.
Immunohistochemistry Five ~,m sections were deparaffinized in xylene (two, 5-10 min incubations) and rehydrated by 3 min incubations in ethanol as follows: two incubations in 100% ethanol followed by two incubations in 95% alcohol and one incubation in 70% alcohol. Once hydrated, sections were rinsed in tap water for 1 min and distilled water for 1 min. Endogenous peroxide activity was blocked by placing slides in 3.0% H~02 for 15 min followed by a 5 min rinse in distilled water. Slides were processed for antigen retrieval using citric acid, pH6Ø Slides were heated to boiling, cooled for 20 min at 25°C, and rinsed in distilled water. Slides were stained using a DAKO
autostainer (DAKO Corporation, Carpinteria, CA). Prior to staining, slides were rinsed and incubated in blocking buffer for 20 min. Blocking buffer is described in the Vectastain ABC kit (Vector Labs, Burlingame, CA) and contains 10 mL TNB (NEN TSA Biotin System kit, Cat#NEL700A, NEN Life Science Products, Boston, MA) and 3 drops of normal (corresponding to the secondary antibody) serum.
Primary antibodies used for staining include:
Osteopontin, diluted at 1:100 (Mouse monoclonal, Cat#MPIIIbIO, Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, IA); ED-1 diluted at 1:500 (anti-macrophage glycoprotein, mouse monoclonal, MAB1435, Chemicon International Inc., Temecula, CA); CD-3 diluted at 1:300 (anti-T-cell, rabbit polyclonal-affinity purified antibody, A0452, DAKO Corporation, Carpineria, CA); ICAM-1 diluted at 1:100 (goat polyclonal-affinity purified, M-l9:sc-1511, Santa Cruz Biotechnology, Santa Cruz, CA); VCAM-1 diluted at 1:100 (goat polyclonal-affinity purified, C-l9:sc-1504, Santa Cruz Biotechnology). Slides were incubated with primary antibodies for 60 min, followed by biotinylated antibodies at a final concentration of 5 ~,L/mL for 30 min at 25°C. Staining was visualized with the Vectastain ABC-AP kit (Vector Laboratories) and diaminobenzidine staining (DAKO Corporation,e Carpinteria, CA). Slides were rinsed in water and counter-stained with hematoxylin for approximately 30 sec. Isotype-matched IgG (Sigma Chemical, St. Louis MO) was used as a negative control for the primary antibodies.

In situ Hybridization for Osteopontin mRNA
RNA probes were generated based on a sequence for rat osteopontin (GenBank accession# NM 008608-1). Briefly, a cDNA fragment of rat osteopontin was generated by RT-PCR using the following primers: forward primer, 5'-TGG
CAC ATT TGT CTT; reverse primer 3'AGC CCA TCC AGTC. The cDNA fragment was inserted into the PCR II plasmid using the TA cloning kit (Invitrogen Corporation, Carlsbad, CA) . Probes were labeled in 100 ~,L in vitro transcription reaction containing: rRNasin (2 U), DNase (0.5 U) , TE Buffer (1X) , rGTP (10 mM) , rCTP (10 mM) , rATP ( 10 mM) , rUTP ( 10 mM) , ( PROMEGA, Madi son, WI ) , 5/~,L
(50~Ci) 33P-UTP (Elkin Pelmer, Boston, MA) and appropriate RNA polymerases (Sp6 RNA Polymerase (20 U/~.L) ; T7 RNA Polymerase (15 U-~.L) , PROMEGA) for 60 min at 37°C. Free label was removed from the reaction using Microcon YM-50 Microconcentrators (Amicon, Bedford, MA).
Sections were deparaffinized in xylene, rehydrated in graded ethanol solutions as described above, and fixed in 4% paraformaldehyde (EMS, Ft. Washington, PA) for 10 min at 4°C. Tissues were then digested with Proteinase K (5 mg/mL; 10 min, 37°C, Roche, Indianapolis, IN) and washed in 0.5 X SSC buffer (Saline-Sodium Citrate buffer) (10 min) . Prehybridization was performed after sequential dehydration in graded series of ethanol, the reverse process as described above for rehydration, followed by incubation in hybridization buffer (50%
formamide, 2 X SSC, 10% dextran sulfate, v/v) for 2 hours at 42°C. Hybridization was performed overnight using hybridization buffer containing tRNA (50 ~,g/mL, Sigma, St. Louis, MO) and the appropriate labeled probe at 55°C. Hybridized tissues were then washed successively in ZX SSC buffer, O.1X SSC-EDTA buffer (O.1X SSC, 1mM EDTA), and 2X SSC buffer for 1 hour 40 min. Slides were finally dehydrated in graded series of ethanol as described above containing NH40Ac (2 min each) and dried in a vacuum desiccator for 1.5 hours at room temperature. Tissues were exposed overnight to a phosphorus screen. Slides were coated with photographic emulsion (Kodak, Rochester, NY) and exposed at 4°C for 3-5 weeks prior to development. Developed slides were counterstained with hematoxylin and eosin.
Principles of TaqMan Analysis The fluorogenic 5'-nuclease assay (TaqMan PCR) using Applied Biosystems' 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) allowed for real time detection/quantitation of a specific gene by monitoring the increase in fluorescence of a gene-specific, dye-labeled oligonucleotide probe. Probes for target and reference genes were labeled at the 5'-end with a 6-carboxyfluorescein (6FAM) reporter dye and at the 3'-end with a 6-carboxy-N,N,N',N'-tetramethylrhodamine (TAMRA) quencher dye. When the probe was annealed to the target gene, fluorescence of 6FAM was prevented by the close proximity of TAMRA. The exonuclease activity of Taq polymerase released the dyes from the oligonucleotide probe by displacing the probe from the target sequence resulting in fluorescence excitation in direct proportion to the amount of target message present. Data analysis was performed using the Sequence Detection System software from Applied Biosystems.

TaqMan Primers and Probes: TGF~i 1, ANP, Collagen I, Collagen III
Primers and probes were designed using Oligo Primer Analysis Software, Version 5.0 (National Biosciences Inc. (NBI)-Wojciech Rychlik, Cascade, CO). Primers were synthesized by Life Technologies (Grand Island, NY) and probes were synthesized by Applied Biosystems.
Primer/probe sets were designed from known sequences of rat genes to be analyzed. All target gene values were normalized to a reference gene, constitutively expressed cyclophilin. Primer/probe sets sequences can be found in Table 8 Table 8 TaqMan RT-PCR Gene Marker Primer/Probe Sets Gene Forward Primer Reverse Probe Primer Transform CACCATCCATGACA ACCTTGCTGTACT TCAGCTCCACAG

ing TGAACC ' GTGTGTCC AGAAGAACTGC

growth factor beta 1 ( TGF(31 ) Atrial TGGGCTCCTTCTCC AGCAGAGCCCTCA CCATATTGGAGC

natriuret ATCAC GTTTG AAATCCCGTATA

is factor C

(ANP ) Collagen ACCAAGGCTGCAAC GCAGGAAGGTCAG CCATACTCGAAC

I CTGGA CTGGAT TGGAATCCATCG

Collagen GGCTTTCAGTTCAG GACTGTCTTGCTC CCTGATCTTCCT

III CTATGG CATTCAC GAAGATGTCCTT

G

Cyclophil CTTGTCCATGGCAA GTGATCTTCTTGC CCACAATGCTCA

in ATGCTG TGGTCTTGC TGCCTTCTTTCA

CC

Cyclooxeg TCAAAGACACTCAG CGGCACCAGACCA CACGTCCCTGAG

enase-2 GTAGA AAGACTT CACCTGCGG

(COX-2) CATGATCT

Osteopont CCAGCACACAAGCA TCAGTCCATAAGC CAGTCGATGTCC

in GACGTT CAAGCTATCAC CTGACGGCCG

Monocyte GCAGGTCTCTGTCA GGCTGAGACAGCA CCTGTTGTTCAC

Chemoattr CGCTTCT CGTGGAT AGTTGCTGCCTG

actant TAGC

Protein-1 (MCP-1) Intercell ACCTGCAGCCGGAA CCCGTTTGACAGA CCGATAGGCAGC

ular AGC CTTCACCAT GGGACACCA

Adhesion Molecule-1 ( I CAM-1) Vascular GAAGCCGGTCATGG GGTCACCCTTGAA TGGCTCCTGATG

Cell TCAAGT CAGTTCTATCTC TTTACCCAATTG

Adhesion ACAGA

Molecule -1 (VCAM-1) Cyclophil AGAGAAATTTGAGG TTGTGTTTGGTCC AAGCATACAGGT

in ATGAGAACTTCAT AGCATTTG CCTGGCATCTTG

TCCAT

All oligonucleotides are written 5' - 3'. Primers are unlabeled and all probes are labeled at the 5' end with 6-carboxyfluorescein (6FAM) reporter dye and at the 3' end with 6-carboxy-N,N,N',N'-tetramethylrhodamine (TAMRA) quencher dye RNA isolation: TGF(31, ANP, Collagen I, Collagen III
RNA was extracted from frozen (-70°C) left ventricle (LV) tissue (approximately 10-20 mg) using 1.5 mL RNA-STAT 60 according to manufacturer's instructions (Leedo Medical Laboratories, Inc., Houston, Texas). Briefly, tissues were homogenized using a tissue homogenizer equipped with a 5 mm probe (Ultra-Turrax T8 Homogenizer, IKA Works, Inc. Wilmington, NC). Following homogenization, an equal volume of molecular grade chloroform (Sigma Chemical Co., St. Louis, Mo.) was incubated with periodic mixing for 10 min at room temperature. Samples were centrifuged at 12,OOOg for 10 min and RNA was precipitated from the top layer by adding an equal volume of molecular grade isopropanol (Sigma Chemical Co.) followed by an overnight incubation at -80°C. RNA was pelleted by centrifugation at 12,OOOg, washed with 75% ethanol, and solubilized in nuclease-free water (Promega, Madison, WI). RNA was diluted and analyzed spectrophotometrically for concentration and purity (A260/A280 = 1.9 - 2.0, with an average yield of 2-5 ~,g RNA).
Reverse Transcription: TGF/31, ANP, Collagen I, Collagen III
Double-stranded CDNA was synthesized by adding 400 ng RNA (4uL) to a final volume of 20 uL containing 15%
nuclease-free water (Promega, Madison, WI), 1X RT Buffer (Life Technologies, Grand Island, NY), 10 mM DTT (Life Technologies), 0.5 mM each of dATP, dTTP, dGTP, dCTP (PE
Biosystems, Foster City, CA), 2.5~,M Oligo d(T)15 (Oligo Therapeutics, InC., Wilsonville, OR), 40 units RNAsin (Promega), and 200 units Superscript II Reverse Transcriptase (Life Technologies). The reactions were performed in thin-walled reaction tubes with caps (Applied Biosystems) to ensure accurate reaction temperatures. Reactions were performed using a GeneAmp 9600 thermal Cycler (Applied Biosystems) according to the following protocol: 1 hour at 37°C, 5 min at 95°C, and 10 min at 4°C.
TaqMan Analysis: TGF~31, ANP, Collagen I, Collagen III
Each PCR reaction contained the following: 2.5 ~,L (50 ng) of each CDNA added to 22.5 ~,L of a PCR mix containing: 38.50 nuclease-free water (Promega), 1X PCR
Buffer II, 2 mM MgCl~, 0.05 U/~,L AmpliTaq Gold (PCR Core Reagent Kit, N808-0228, Applied Biosystems), 300 nM each of a forward and a reverse primer (Life Technologies), 200 nM probe (Applied Biosystems) and 200 ~M each of dATP, dTTP, dGTP, and dCTP (Applied Biosystems). Single reactions were set up in MicroAmp optical tubes with MicroAmp optical caps (Applied Biosystems) and loaded into the 7700 Sequence Detector. The following protocol was applied to all reactions: 10 min at 95°C (polymerase activation), 40 cycles of 10 seconds at 95°C
(denaturation) and 1 min at 57°C (annealing).
TaqMan Primers and Probes: COX-2, Osteopontin, MCP-1, ICAM-1, VCAM-1 All primers and probes were designed using Primer Express software supplied with the 7700 Sequence Detection System and synthesized by Applied Biosystems.
Standard curves using 5-fold dilutions of total RNA
(from 200 ng to 320 pg) were performed to determine the efficiency of each primer/probe set in the TaqMan reaction prior to the analysis of the experimental samples. Primer/probe sets were designed from known sequences of rat genes to be analyzed. All target gene values were normalized to a reference gene, constitutively expressed cyclophilin. Primer/probe set sequences can be found in Table 8.
RNA isolation: COX-2, Osteopontin, MCP-1, ICAM-1, VCAM-1 RNA was extracted from frozen (-80°C) rat heart tissue using the Totally RNA Isolation Kit (Ambion, Inc., Austin, TX). Tissue was crushed using a stainless steel mortar and pestle, which had been chilled to -80°C and transferred to a Bounce homogenizer (Kontes, Vineland, NJ) containing 3-10 mL cold denaturation buffer. Tissue was homogenized and transferred to a sterile, 15 mL

polypropylene centrifuge tube. An equal volume of phenol: chloroform:isoamyl alcohol (25:24:1) was added, samples were shaken vigorously for 1 min, and incubated on ice for at least 15 min. Samples were centrifuged for 30 min at 10,OOOg. The aqueous phase was removed, 1/10 volume of a sodium acetate solution (3.0 M NaOAc pH
4.5) was added, samples were shaken or inverted for 10 seconds, and acid-phenol (premixed with isoamyl alcohol):chloroform (5:1, Ambion, Inc.) was added at an volume equivalent to the starting sample volume.
Samples were shaken vigorously for 1 min, followed by a 15-min incubation on ice, and centrifuged for 30 min at 10,OOOg. The aqueous phase removed and placed in a clean polypropylene tube,. An equal volume of isopropanol (Sigma, St. Louis, MO) was added and the samples were mixed and incubated overnight at -20°C.
The samples were centrifuged for 30 min at 10,000g, the supernatant was removed and the RNA pellet was resuspended in DNAse/RNAse-free water. Samples were frozen at -80°C for at least 2 hours, thawed on wet ice, and diluted for quantitation.
All RNA was further purified by DNase digestion to remove genomic DNA and LiCl precipitation to remove carbohydrates. Each RNA (100 ~,g) was incubated for 45 min at 37°C with 1 unit of DNAse (Roche Diagnostics, Indianapolis, IN) and 10 units RNAse inhibitor (Applied Biosystems, Foster City, CA) in a buffer containing 40 mM Tris pH 7.8, 6 mM MgCl2, 10 mM CaCl2. The DNAse and buffer were removed using the RNeasy Mini protocol for RNA cleanup (Qiagen, Valencia, CA). The RNA was then precipitated with 7.5M LiCl/50 mM EDTA (Ambion, Inc., Austin, TX) in a volume equal to half the sample volume, incubated overnight at -20°C, and centrifuged for 30 min at 13-16,OOOg at 4°C. All RNA was frozen for at least 2 hours at -80°C, thawed, diluted, and analyzed spectrophotometrically for concentration and purity.

TaqMan Analysis: COX-2o Osteopontin, MCP-1, ICAM-1, TaqMan reactions were performed as follows. Ten ~,L (200 ng) of total RNA (DNAsed and LiCl precipitated) was 10 added to 15 ~,L of a RT-PCR reaction mix containing: 12.5 ~,L of 2X One-Step PCR Master Mix without uracil-N-glycosylase (contains AmpliTaq Gold DNA Polymerase, dNTPs with dUTP, passive reference, and optimized buffer components), 0.625 ~,L of a 40X MultiScribe and RNAse 15 Inhibitor Mix, 0.625 ~,L of 20 ~M forward primer, 0.625 ~,L of 20 ~,M reverse primer, 0.5 ~L of 5 ~,M TaqMan probe, and 0.125 ~.L of DNAse/RNAase-free water. Reactions were set up in duplicate in MicroAmp optical 96-well reaction plates with MicroAmp optical caps or adhesive covers 20 (Applied Biosystems) and loaded into the 7700 Sequence Detector. The following protocol was applied to all reactions: 30 min at 48°C (reverse transcription), 10 min at 95°C (inactivation of reverse transcriptase and polymerase activation), 40 cycles of 15 seconds at 95°C
25 (denaturation), and 1 min at 60°C (annealing).
Hydroxyproline Assay Myocardial hydroxyproline concentration was measured by a Colorimetric assay that quantifies the reaction 30 between oxidized hydroxyproline, and p-dimethylaminobenzaldehyde as described previously (4).
Briefly, tissues (180-250 mg) were dried for 18 hours at 60°C using a Reacti-Therm heating block (Pierce, Rockford, IL) and weighed. Dried tissues and a positive collagen control (Bovine Collagen Type I, Sigma, St.
Louis, MO) were hydrolyzed with 2 mL 6N HCl for 3 hours at 150°C in the Reacti-Therm heating block. Acid was evaporated under nitrogen gas, samples were rehydrated in 1 mL of citrate-acetate buffer (0.7 M NaOAc, 0.2 M
citrate, 45 mM citric acid, pH 6.0) in the presence of 4 mL isopropanol, and filtered through a 0.45 ~m Millex LCR filter (Gelman Sciences, Ann Arbor, MI).
Hydroxyproline content was measured by incubating 60 ~,L
of hydrolyzed sample or collagen standard with 350 ,~.L
citrate-acetate-isopropanol buffer (citrate-acetate buffer with 40o isopropanol, v/v) and 100 ~,L of 300 mM
Chloramine T (J.T. Baker, Phillipsburg, NJ) for 5 min at 25°C. Erlich's Reagent (1.25 mL, 3.5 M p-dimethylaminobenzaldehyde in 70% perchloric acid with 80% isopropanol, v/v) was added for visualization and quantitation of hydroxyproline. Samples were incubated at 60°C for 30 min, cooled to room temperature, and absorbance was monitored at 558 nm. Hydroxyproline content was quantitated from a freshly prepared standard curve of trans-4-hydroxy-L-proline (Sigma, St. Louis, MO). All samples and standards were performed in duplicate.
.Statistical Analysis Data were analyzed using one-way analysis of variance (ANOVA). Because the assumptions of normality within groups and equality of variance across groups could not be consistently met, the analysis was performed on the rank transformed values of the raw data (nonparametric analysis). The alpha=0.05 level of significance was used for the planned comparisons between the means. The Least Significant Differences (LSD) method was used for planned comparisons between groups. Data were analyzed using PROC TTEST in the SAS statistical software package (SAS PC, version 6.12,,SAS Institute, Cary, NC). All data are reported as mean ~ standard error of the mean (SEM) .
Animal Exclusioxi Three animals died during the experiment: rat #17 (aldosterone + salt group, found dead after 24 days of infusion), rat #64 (aldosterone + salt group, died following surgery), and rat 5 (vehicle group, died following surgery). Additional animals were excluded if multiple parameters were found not to represent the treatment group to which they were assigned (e. g. more than 3 standard deviations from the mean for that treatment group). Three such animals were excluded from the study: rat #57 (from 7-day protocol, aldosterone +
salt group), rat #97 (from 14-day protocol, aldosterone+
salt group), and rat 24 (from 30-day protocol, 100 mg/kg/day eplerenone group). These three animals demonstrated expression of inflammatory marker genes (COX-2, Osteopontin, MCP-1, ICAM-l, and VCAM-1} that were greater than 3 standard deviations from the mean for the treatment group. Rat #24 was also excluded as a result of telemetry unit dysfunction. Values generated for these animals are shown in Table 9.10-Table 9.19, WO 03/063908 ~ PCT/US03/02923 separated from the data for the other animals in the data tables.
Table 9.10 Ix~,dividual data used for Table 10 Control: vehicle + salt Rat 1 2 4 6 7 8 9 10 #

Day Systolic Blood Pressure (mmHg) -- - No data were collected due to technical difficulties.

Table 9.10 (continued) Aldosterone + salt Rat 11 12 13 14 15 18 Day Systolic Blood Pressure (mmIIg) -- - No data were collected due to technical difficulties.

Table 9.10 (continued) Eplerenone + aldosterone + salt Rat 21 23 25 26 27 28 29 30 24*

Day Systolic Blood Pressure (mmHg) 17~ 148 141 143 182 149 148 143 160 174 ---- - No data were collected due to technical 5 difficulties.
* Data from this animal were not considered for statistical analysis and not included in the final results.

Table 9.11 Individual data used for Table 11 Control: vehicle + salt Left Right Final Left Right Ventricle R B t l Tibia W Ventricle ~P
t d i V ht / ' l t i i a o en r t e ht /
y r en L g Wei c c eng g # Weight a Weight a Weight Tibia (p,U) (cm) Tibia Lengt (g) (mg) (mg) Length (mg/cm) (mg/cm) 0.

291 771 194 3.9 198 50 90 0.

283 699 155 3.8 184 41 70 3.

2g4 696 166 3.8 183 44 59 3.

267 562 175 3.8 148 46 96 1.

268 636 178 3.8 167 47 11 0.

273 709 185 3.7 192 50 94 0.

269 699 197 3.8 184 52 64 1.

245 612 189 3.8 161 50 06 0.

2g6 667 190 3.8 176 50 93 1.

245 616 149 3.8 162 39 10 1~

Mea 271 667 178 3.8 175 47 49 SEM

19 5 0.01 5 1 38 5 Table 9.11 (continued) Aldosterone + salt Tibi Left Right Final Left Right a Ventricle Ventricle Rat Body VentriclVentricl ANP
L W W
i i ht / ht /

eng e e g g # Weight a Weighta Weight ('~U) (g) (mg) (mg) th ibia Lengt ibis Lengt (cm) (mg/cm) (mg/cm) 11.

58 266 784 183 3.8 206 48 92 3.9 59 271 719 178 3.6 200 49 9 13.

60 299 719 223 3.9 184 57 41 61 286 779 185 3.9 200 47 3.6 9.0 274 746 168 3.8 196 44 9 .

27& 620 154 3.8 163 41 13 6.1 -- g49 197 3.9 218 51 3 3.8 266 674 174 3.7 182 47 8 8.1 Mea 277 736 183 3.8 194 . 48 5 0.0 1.5 SEM

-- - No data were collected due to technical difficulties.
57* 267 778 208 3 8 205 55 I13 32I
* Data from this animal were not considered for 5 statistical analysis and not included in the final results.
Table 9.11 (continued) Eplerenone + aldosterone + salt Tibi Left Right Final Left Right a Ventricle Ventricle Rat Body entricl Ventricle ANP
L W W
ht / i i ht /

eng e e g g # weight a Weight Weight (AU) th ibia Lengt ibis Lengt (g) (mg) (mg) (cm) (mg/cm) (mg/cm) 1.

306 859 216 3.9 220 55 26 1.

295 712 181 3.8 187 48 81 286 618 154 3.7 167 42 59 2.

277 658 174 3.8 173 46 58 4.

295 754 192 3.8 198 51 48 4.

281 733 171 3.8 193 45 98 3.

273 726 181 3.8 191 48 82 3.

74 286 696 190 3.8 183 50 59 0.

75 -- 700 170 3.8 184 45 95 3.

76 276 688 187 3.8 181 49 67 Mea 2~

286 714 182 3.8 188 48 77 SEM 0'~ 0.

-- - Lvo data were collected due to technical difficulties.
Table 9.12 Individual data used for Table 12 Control: vehicle + salt Left Right a Final Left Right Tibia entricle entricleANP
Body Ventricle Ventricl Weight Wei ht # Length/ g / (AU) WeightWeight Weight (cm) Tibia (g) (mg) (mg) . Tibia Length Length (mg/cm) (mg/cm) 87 319 760 188 3.9 195 48 0.16 88 337 782 238 3.9 201 61 0.92 89 322 665 179 3.9 171 46 0.36 90 322 802 208 3.8 211 55 0.89 91 -- 742 174 3.8 195 46 7.04 92 327 790 200 3.8 208 53 1.89 93 324 747 303 3.8 197 80 3.33 94 301 826 184 3.80 217 48 1.80 95 303 745 178 3.8 196 47 1.08 96 295 756 206 3.9 194 53 0.17 127 313 777 174 3.9 199 45 nd 128 295 677 178 3.8 178 47 nd 129 278 657 165 3.8 173 43 nd ea 311 748 198 3.8 195 52 1.76 'SE 5 15 10 0.01 ~ 4 3 0.66 -- - m~ uaza were collected due to technical difficulties.
nd = No data were reported due to insufficient mRNA
sample .
Table 9.12 (continued) Aldosterone + salt Final Left Right Tibi Left Right a Ventricle Ventricle Rat Body VentriclVentricl '~P

# Weight a weighta Weight Leng Weight / weight / ' (AU) (g) (mg) (mg) th ibia Lengt ibia Lengt (cm) (mg/em) (mg/cm) 98 4.5 298 846 194 3.8 223 51 8 99 261 784 ~ 189 ~ 3.8 206 I 50 7 ~ ~ ~ 7 100 7'3 307 912 208 3.9 234 53 4 101 4.1 242 720 174 3.8 189 46 8 102 1.5 307 923 217 3.9 237 56 9 103 3~8 17.

104 6.4 308 894 216 3.9 229 55 8 105 8.0 290 859 171 3.9 220 44 8 106 2.5 264 750 153 3.8 197 40 1 130 275 818 202 3.8 215 53 nd 131 193 746 195 3.7 202 53 nd 132 215 700 172 3.6 194 48 nd Mea 6.7 270 817 189 3.8 214 50 0 SEM 0'0 1.5 na = lvo aata were reported. d.ue to insufficient mRNA
sample.
97* 235 809 178 3.9 207 46 5.96 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.12 (continued) Eplerenone + aldosterone + salt Final Left Right Tibi Left Right Rat Body Ventricl Ventricla Ventricle Ventricle ~

# weight a Weight a weightLeng Weight / Weight / (p,,U) (g) (mg) (mg) th ibia Lengt ibia Lengt (cm) (mg/cm) (mg/cm) 133 281 804 182 3.8 212 48 nd 134 2.8 304 898 188 3.8 236 49 4 135 3.2 293 789 176 3.8 208 46 2 136 6.3 268 851 189 3.9 221 49 9 137 4.0 267 668 139 3.8 176 37 4 138 25.9 247 833 371 3.7 225 100 0 139 5.5 296 886 193 3.8 233 51 2 140 3.5 291 756 188 3.8 199 49 7 2.2 297 751 158 3.8 198 42 9 142 8.3 264 795 155 3.7 215 42 7 143 4.2 302 915 225 3.9 235 58 4 6.6 Mea 283 813 197 3.8 214 52 4 0.0 2.2 SEM

nd = No data were reported due to insufficient mRNA
sample.
Table 9.13 Individual data used for Table 13 Control: vehicle + salt Final Left Right Tibi Left Right a Ventricle Ventricle Rat Body Ventricl 'entricl ANP

# Weight a Weight e WeightLeng Weight / Weight / (gU) (g) (mg) (mg) th ibia Lengt ibia Lengt (cm) (mg/cm) (mg/cm) 1 0.9 308 686 160 4.0 172 40 5 2 0.3 337 763 194 4.1 186 47 0 4 0.1 316 728 162 4.0 182 41 2 1.0 343 721 162 4.1 176 40 6 7 1.9 291 664 153 4.0 166 38 3 8 0.2 294 612 180 4.1 149 44 4 1.1 291 613 141 4.0 153 35 7 10 0.1 332 812 184 4.2 193 44 1 Mea 0.7 314 700 167 4.1 172 41 4 SEM 0.0 0.2 Aldosterone + salt Tibi Left Right Final Left Right Ventricle Rat Body VentriclVentricla Ventricle Weight / ANP

# Weight a Weighta WeightLeng Weight / Tibia (AU) (g) (mg) (mg) th ibia Lengt Length (cm) (mg/cm) (mg/cm) .

289 934 196 4.0 234 49 59 .

219 726 148 3.8 191 39 11 .

289 963 215 3.9 247 55 83 14 18.

282 942 176 3.9 242 45 90 .

290 1030 224 3.9 264 57 83 16 23.

267 837 173 3.9 215 44 43 18 15.

319 962 220 3.9 247 56 14 19 6.7 263 873 187 4.0 218 47 7 20 20.

234 919 185 3.8 242 49 97 Mea 20.

272 910 192 3.9 233 49 17 SEM 0-0 3.3 Table 9.13 (continued) Eplerenone + aldosterone + salt Final Left Right Tibi Left Right Rat Body Ventricl Ventricla Ventricle Ventricle ~P

# Weight a Weight a WeightLeng Weight / Weight / (AU) (g) (mg) (mg) th ibia Lengt ibia Lengt (cm) (mg/cm) (mg/cm) 21 1.9 310 873 177 3.9 224 45 3 22 1.1 343 908 202 4.1 233 52 5 23 4.8 334 899 200 3.9 231 51 9 25 21.

299 1063 209 3.9 273 54 26 26 10.

361 958 187 3.9 246 48 63 27 20.

351 1129 242 3.9 289 62 25 10.

316 929 189 3.9 238 48 20 4.8 352 805 181 4.0 206 46 2 7.6 317 861 195 3.9 221 50 7 9.2 Mea 331 936 198 3.9 240 51 0 0.0 2.4 SEM

24* 273 822 178 3.9 211 46 13.45 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.14 Individual data used for Table 14 Control: vehicle + salt Myocardial Interstitial ollagen-ollagen-Rat Collagen ydroxyproline I III
Necrosis Volume ( 0 - 4 ) ( N~g /mg ) mRNA mRNA
Fraction (%) (AU) (AU) 47 0.0 2.9 5.11 1.72 1.39 48 0.0 7.1 5.72 0.63 0.80 49 0.0 3.1 3.15 1.97 2.00 50 0.0 4.1 2.37 1.08 1.19 51 0.0 3.4 2.23 1.40 1.09 52 0.0 4.5 2.48 0.73 0.92 53 0.0 2.3 2.35 1.22 1.27 54 0.0 6.6 2.42 0.78 0.91 55 0.0 4.1 4.68 0.54 0.70 56 0.0 6.3 5.21 0.93 0.61 ea 0.0 4.4 3.57 1.10 1.09 SEM 0.0 0.5 0.45 0.15 0.13 Table 9.14 (continued) Aldosterone + salt Interstitial ollagen-ollagen-Rat Myocardial Collagen IydroxyprolineI III

Necrosis Volume (~,g/mg) mRNA mRNA

(0-4) Fraction (%) (AU) (AU) 58 0.0 nd 4.48 0.84 0.65 59 0.0 3.2 4.06 1.40 1.29 60 0.0 6.5 2.32 1.97 1.67 61 0.0 nd 2.14 1.89 1.67 62 0.0 6.1 2.18 1.36 1.59 63 0.0 6.9 2.31 1.05 1.59 65 0.0 6.5 2.10 1.33 1.58 66 0.0 4.4 2.22 1.07 1.30 Mean 0.0 5.6 2.73 1.36 1.42 SEM 0.0 0.6 0.34 I 0.14 ( 0.12 nd = No data were reported due to insufficient mRNA
sample.
57* 0 . 0 3 . 1 3 . 86 - ~1-.71 I 1 . 15 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.14 (continued) E~lerenone + aldosterone + salt Myocardial Interstitial ollagen- ollagen-Rat Collagen ydroxyproline I III
# Necrosis Volume m mRNA mRNA
(8-4) (N~9'/ g) Fraction (AU) (AU) (%) 67 0.0 4.3 2.02 0.62 0.93 68 0.0 7.2 4.18 0.92 0.95 69 0.0 2.9 4.08 0.29 0.43 70 0.0 3.3 3.96 1.79 1.25 71 0.0 4.2 4.26 0.78 1.03 72 0.0 6.6 4.17 0.85 1.14 73 0.0 4.4 1.90 0.29 0.45 74 0.0 4.9 1.53 0.42 0.64 75 0.0 8.8 2.08 1.28 1.33 76 0.0 6.9 2.41 1.21 2.71 Mean 0.0 5.4 3.06 0.85 1.09 SEM 0.0 0.6 0.36 0.15 0.21 Table 9.15 Individual data used for Table 15 Control: vehicle + salt Collagen ollagen- ollagen-Rat Myocardial Volume IydroxyprolineI III

Necrosis # Fraction (~,g/mg) mRNA mRNA

(0-4) (%) (AU) (AU) g7 0.0 4.6 . 2.03 0.90 0.96 88 0.0 3.9 2.20 1.60 1.60 89 0.0 6.5 4.51 0.92 0.80 90 0.0 4.4 4.07 0.58 0.65 91 0.0 6.3 4.93 1.28 1.42 92 0.0 3.1 4.00 0.94 1.05 93 0.0 4.9 2.89 1.14 1.00 94 0.0 3.9 3.24 1.07 1.02 95 0.0 3.2 3.21 1.56 1.00 96 0.0 3.7 3.16 0.80 0.56 127 0.0 4.9 2.66 nd nd 128 0.0 6.0 2.70 nd nd 129 0.0 6.1 2.84 nd nd Mean 0 . 0 4-. 7 3 . 2~ 1 . 0$-- 1 . 01 SEM 0.0 ~ 0=-4 ~ __-0.24 -- I O--10 0.10 I

nd = No data were reported due to insufficient mRNA
sample.
Table 9.15 (continued) Aldosterone + salt Myocardial Collagen Rat Ydroxyproline ollagen- ollagen-ecrosis (0- Volume I III
4) Fraction ( g~mg) (%) mRNA mRNA
(AU) (AU) 9g 0.0 4_4 2.89 1.15 0,76 99 1.0 5.4 2.91 2.31 1.80 100 0.0 3.2 6.28 0.25 0.44 101 0.0 5.9 5.63 1.89 1.39 102 0.0 4.6 4.83 2.03 1.17 103 1.0 3.9 5.64 1.00 1.24 104 0.0 4.8 5.29 1.20 1.06 105 0.0 4.6 2.76 1.70 1.31 106 1.0 5.9 2.68 0.43 0.59 130 0.0 3.4 2.60 nd nd 131 3.0 6.4 3.00 nd nd 132 3.0 9.0 3.99 nd nd Mean 0.8 5.1 4.04 1.33 1.08 SEM 0.3 0.5 0.40 0.24 0.14 nd = No data were reported due to insufficient mRNA
sample.
97* 3.0 3.2 2.73 2.69 1.22 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.15 (continued) Eplerenone + aldosterone + salt Myocardial Collagen ollagen- ollagen-Rat Ydroxyproline I III

ecrosis (0- Volume (~'g~mg) ~.NA mRNA

4) Fraction (AU) (AU) (%) 133 1.0 4.1 2.95 0.86 0.60 134 0.0 6.2 5.97 0.86 1.19 135 1.0 3.9 6.52 0.90 1.16 136 0.0 3.7 5.35 1.65 1.24 137 0.0 4.2 6.80 1.14 1.70 138 0.0 3.5 5.32 1.44 1.81 139 1.0 3.3 2.72 0.50 0.60 140 0.0 3.7 3.13 1.24 1.61 141 0.0 5.2 2.41 1.69 2.21 142 2.0 5.6 2.81 2.03 1:80 143 0.0 6.0 5.03 3.02 3.77 Mean0.5 4.5 4.46 1.39 1.61 SEM 0.2 0.3 0.50 0.21 0.26 Table 9.16 Individual data used for Table 16 Control: vehicle + salt Myocardial Collagen ollagen-ollagen-Rat ecrosis (0- Volume Ydroxyproline I III
4) Fraction (~g~mg) ANA mRNA
(o) (AU) (AU) 1 0.0 4.3 2.00 1.69 1.43 2 0.0 4.1 2.71 0.90 0.98 4 0.0 6.4 2.95 1.65 1.02 ~

6 0.0 7.9 3.02 0.90 1.28 7 0.0 5.8 2.81 0.97 0.62 8 0.0 7.7 5.84 1.03 0.54 9 0.0 6.0 5.45 0.69 0.94 10 0.0 7.1 7.03 0.92 0.48 Mean0.0 6.2 3.98 1.09 0.91 SEM 0.0 0.5 0.65 0.13 0.12 Aldosterone + -salt Myocardial Collagen ollagen-ollagen-Rat ecrosis (0- Volume ~YdroxyprolineI III
4) Fraction (~'g~mg) ANA mRNA
(%) (AU) (AU) 11 1.5 6.6 7.24 2.20 0.75 12 2.5 8.8 8.01 2.02 0.58 13 3.0 7.2 3.62 5.88 1.99 14 2.0 7.1 3.69 1.05 0.72 15 3.0 9.3 4.00 1.32 2.04 16 0.5 6.8 3.54 2.02 1.43 18 2.0 4.0 3.07 1.98 1.82 19 0.3 7.2 3.25 1.63 1.89 20 3.5 14.5 3.09 2.54 1.28 Mean 2.0 7.9 4.39 2.29 1.39 SEM 0.4 1.0 0.62 0.47 0.20 Table 9.16 (continued) Eplerenone + aldosterone + salt Myocardial Collagen ollagen-ollagen-Rat ecrosis (0- Volume Ydroxyproline I III
# 4) Fraction (~'g~mg) ANA mRNA
(%) (AU) (AU) 21 0.0 3.4 5.18 1.89 0.95 22 0.0 5.0 6.11 1.54 0.72 23 0.0 6.5 5.17 2.65 1.37 25 0.0 7.9 6.40 1.97 0.89 26 0.0 7.1 2.73 2.98 1.26 27 0.0 6.3 2.84 2.65 1.87 28 0.0 6.1 2.97 2.90 1.66 29 0.0 5.4 2.82 2.88 2.89 30 0.0 7.8 2.72 3.35 2.16 Mean 0.0 6.2 4.10 2.53 1.53 SEM 0.0 0.5 0.53 0.20 0.23 24* 0.0 4.4 5.75 2.01 0.73 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.17 Individual data used for Table 17 Control: vehicle + salt Rat COX-2 Osteoponti MCP1 ~TGF-~CiICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 47 nd nd nd 1.32 nd nd 48 nd nd nd 0.66 nd nd 49 nd nd nd 1.46 nd nd 50 0.57 1.28 1.13 0.72 1.15 1.19 51 1.04 0.94 1.00 1.17 0.94 nd 52 0.99 0.73 0.71 0.80 1.17 1.17 53 0.87 1.00 0.84 1.11 0.82 0.60 54 1.88 nd nd 0.90 nd nd 55 1.01 nd nd 0.52 nd nd 56 nd 1.66 1.67 1.50 1.00 0.86 Mean 1.06 1.12 1.07 0.98 1.02 0.96 SEM 0.18 0.16 0.17 0.12 0.07 0.14 na = lvo aaza was reported due to insufficient mRNA
sample .

Table 9.17 (continued) Aldosterone + salt Rat COX-2 Osteoponti MCP1 TGF-~3 ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 58 2.10 1.84 2.05 1.23 1.39 3.49 59 0.70 0.84 1.78 0.98 0.80 0.85 60 2.01 0.95 3.06 1.31 1.09 2.06 61 2.95 1.05 2.36 1.89 1.61 2.51 62 2.05 1.08 1.95 1.22 1.11 1.65 63 1.94 4.92 2.33 1.45 1.15 0.61 65 3.54 3.29 3.14 1.47 1.56 0.94 66 2.45 1.32 2.40 1.21 1.06 0.27 Mean 2.22 1.91 2.38 1.35 1.22 1.55 SEM 0.29 0.51 0.17 0.09 0.10 0.39 57* 0.82 28.64 5.17 1.35 1.68 5.23 * Data from this animal were not considered for statistical analysis and not included in the final .
results.
Table 9.17 (continued) Eplerenone + aldosterone + salt Rat COX-2 Osteoponti MCP1 TGF-~3 ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 67 1.19 0.54 2.35 0.80 0.91 0.67 68 2.85 1.24 1.60 0.81 0.89 0.58 69 0.60 0.52 0.85 0.51 0.89 0.22 70 nd nd nd 1.31 nd nd 71 1.16 0.27 0.83 0.80 0.40 0.57 72 0.82 0.60 1.74 1.02 1.23 nd 73 1.86 1.13 2.38 0.61 nd nd 74 nd nd nd 0.84 nd nd 75 0.60 0.96 0.67 1.51 0.58 0.53 76 0.91 0.75 2.03 1.64 1.00 1.00 Mean 1.25 0.75 1.56 0.99 0.83 0.56 SEM 0.29 0.12 0.25 0.12 0.10 0.08 nd = No data were reported due to insufficient mRNA
sample.

Table 9.18 Individual data used for Table 18 Control: vehicle + salt Rat COX-2 Osteoponti MCP1 TGF-~(i ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 87 1.69 1.28 1.28 1.21 1.45 0.92 88 0.74 1.13 0.94 1.19 1.11 0.64 89 nd nd nd 1.00 nd nd 90 1.00 0.94 0.73 0.84 1.14 nd 91 1.43 1.00 1.38 1.32 1.23 0.93 92 0.61 1.28 0.91 1.26 0.98 1.00 93 0.84 1.40 1.00 0.86 0.94 1.35 94 1.18 0.87 1.05 0.82 1.00 nd 95 nd nd nd 1.00 nd nd 96 nd nd nd 0.74 nd nd 127 nd nd nd nd nd nd 128 nd nd nd nd nd nd 129 nd nd nd nd nd nd Mean 1.07 1.13 1.04 1.02 1.12 0.97 SEM 0.15 0.08 0.08 0.07 0.07 0.11 na = loo exaLa were reported due to insufficient mRNA
sample.
Table 9.18 (continued) Aldosterone + salt Rat COX-2 Osteoponti MCP1 TGF-~3 ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 98 nd nd nd 1.26 nd nd 99 7.39 8.14 2.42 1.85 1.16 0.89 100 1.83 1.02 1.87 0.55 1.18 0.69 101 5.80 6.19 4.59 1.91 1.75 0.84 102 2.59 4.06 3.19 1.49 1.15 0.72 103 6.63 12.04 3.34 1.18 1.91 2.23 104 4.18 2.35 1.91 1.32 1.19 1.03 105 3.71 8.25 2.50 1.27 1.82 1.65 106 2.62 10.41 2.22 0.56 1.57 1.24 130 nd nd nd nd nd nd 131 nd nd nd nd nd nd 132 nd nd nd nd nd nd Mean 4.34 6.56 2.76 1.27 1.47 1.16 SEMI 0.72 ~ 1.37 ~ 0.32 ~ 0.16 0.12 I 0.19 I

nd =
No data were reported due to insufficient mRNA
sample.

97*~ 23.34 ~ 81.29 ~ 5.88 I 1.29 I 1.84 I 1.75 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.18 (continued) Eplerenone + aldosterone + eali-.
Rat COX-2 Osteoponti MCP1 TGF-~i ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 133 1.56 4.03 1.78 0.58 1.20 0.54 134 1.04 1.00 1.37 0.62 1.36 0.66 135 0.70 0.77 1.27 1.04 0.95 0.61 136 1.41 8.43 1.75 1.42 1.26 0.61 137 3.78 1.59 1.60 1.29 1.56 0.67 138 1.86 3.97 1.24 1.49 0.98 0.86 139 6.19 3.93 1.92 0.71 1.51 1.21 140 1.87 2.13 1.24 1.21 0.79 1.00 141 0.99 0.72 1.89 1.44 0.98 0.68 142 1.92 4.76 2.21 1.69 1.72 1.60 143 0.86 0.99 1.20 2.41 0.83 0.68 Mean 2.02 2.94 1.59 1.26 1.19 0.83 SEM 0.49 0.72 0.10 0.16 0.09 0.10 Table 2.19 Individual data used for Table 19 Control: vehicle + ~alt-Rat COX-2 Osteoponti MCP1 TGF-~i ICAM VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 1 1.15 0.81 2.39 0.53 1.01 0.96 2 1.75 1.46 1.79 0.52 2.29 1.93 4 0.96 0.57 1.00 1.00 0.99 nd 6 0.95 0.82 0.81 1.19 1.60 1.38 7 0.86 1.13 0.52 1.00 nd nd 8 1.07 1.16 0.53 1.68 0.55 0.45 9 1.00 1.00 1.52 0.90 0.96 1.00 nd nd nd 1.24 nd nd Mean 1.11 0.99 1.22 1.01 1.23 1.14 SEM 0.11 0.11 0.27 0.13 0.25 0.25 ~~~ ua~a. wire reporzea aue to lnsutticient mRNA
sample .
Aldosterone + salt Rat COX-2 Osteoponti MCP1 TGF-~i ICAM VCAM

# (AU) (AU) (AU) (AU) (AU) (AU) 11 nd nd nd 1.41 nd nd 12 4.26 13.13 3.94 1.27 nd nd 13 4.81 11.43 7.19 2.11 2.67 3.48 14 nd nd nd 1.20 nd nd 1.54 13.78 1.61 1.95 1.63 1.87 16 nd nd nd 1.49 nd nd 18 3.10 7.97 9.35 0.83 1.69 2.99 19 5.28 18.44 2.30 0.54 1.50 1.64 8.20 14.88 2.86 1.21 1.54 0.72 Mean4.53 X3.27 4.54 1.33 1.81 2.14 SEM 0.92 1.43 1.25 0.16 0.22 0.49 na = 1vo aata were reported due to insufficient mRNA
sample.
Table 9.19 (continued) Eplerenone + aldosterone + salt Rat COX-2 Osteoponti MCP1 TGF-~i ICAM 'VCAM
# (AU) (AU) (AU) (AU) (AU) (AU) 21 2.44 1.53 2.11 1.00 1.54 1.42 22 0.55 3.28 1.70 1.49 2.06 1.29 23 1.97 1.98 2.21 1.40 1.01 1.49 3.41 8.91 1.38 1.31 1.21 1.27 26 3.71 1.88 2.10 0.96 1.26 0.79 27 3.04 1.97 2.02 1.93 1.06 0.52 28 2.11 1.28 1.43 1.54 0.60 0.57 x 29 1.34 1.43 5.58 1.32 0.99 0.61 1.92 1.01 2.11 0.89 nd 1.42 Mean 2.28 2.59 2.29 1.32 1.22 1.04 SEM 0.33 0.82 0.42 0.11 0.15 0.14 nd = No data were reported due to insufficient mRNA
sample.
24* 12.21 54.57 8.14 1.35 2.92 4.01 10 * Data from this animal were not considered for statistical analysis and not included in the final results 15 Results Blood pressure Blood pressure remained normal in vehicle + salt controls throughout the experiment (Table 10).
Aldosterone + salt induced a progressive increase in 20 blood pressure with time. In animals receiving eplerenone + aldosterone + salt, systolic blood pressure was significantly reduced at days 8-30. However, blood pressure remained elevated compared to vehicle + salt controls.
Table 10. Effects of aldosterone + salt treatment alone or in combination with eplerenone on blood pressure over time Systolic Pressure (mmHg) Blood Day Vehicle ldosterone Eplerenone + n + n + n salt salt aldosterone +
salt 4 123 1 4 133 4* 8 130 2*

5 125 1 4 137 4* 8 132 2*

6 130 1 4 148 5* 8 139 3*

7 132 1 4 155 5* 8 143 3*

8 132 1 4 156 4* 8 142 3*# 9 131 1 4 164 5* 8 142 3*# 9 127 2 7 168 6* 8 142 2*# 9 11 128 2 7 171 6* 8 143 3*#

12 129 2 7 178 6* 8 145 3*# 9 13 128 3 7 182 6* 8 147 3*# 9 14 131 4 7 182 6* 9 150 4*# 9 130 2 7 181 5* ~ 148 4*# 9 16 129 2 7 187 6* 9 150 4*#

17 130 2 7 195 7* 9 154 5*# 9 18 131 3 7 196 6* 9 157 5*# 9 19 127 2 7 200 6* 9 160 5*# 9 126 3 7 203 5* 9 160 5*# 9 21 127 2 7 208 4* 9 165 6*# 9 22 128 1 7 209 4* 9 167 6*# 9 23 131 2 7 208 4* 9 172 6*# 9 24 132 2 7 210 3* 9 174 6*# 9 130 2 7 210 4* 9 176 6*# 9 26 131 2 7 210 3* 9 180 7*# 9 10 These data are expressed graphically in Figure 1.
Values are mean ~ SEM of values obtained every 5 min over 24-hour period.
*Significantly different from vehicle + salt, p<0.05.

# Significantly different from aldosterone + salt, p<0.05.
Body weight, Myocardial Hypertrophy and ANP
Body weights were significantly lower in animals receiving aldosterone + salt treatment at days 7, 14, and 30 compared to vehicle + salt normotensive controls (Tables 11-13). The decrease in body weight induced by aldosterone + salt treatment was significantly attenuated by administration of eplerenone at day 30 (Table 11). Significant left and right ventricular hypertrophy occurred in response to aldosterone + salt treatment. Left ventricular hypertrophy was evident after 7 days of aldosterone + salt treatment (Table 11) whereas right ventricular hypertrophy was only evident after 30 days of aldosterone + salt treatment (Table 13). Eplerenone did not impact absolute ventricular weights or ventricular weight to tibia length ratios induced by aldosterone + salt treatment (Tables 11-13).
Significant elevations in atrial natiuretic peptide (ANP) mRNA levels were also observed in animals treated with aldosterone + salt (Tables 11-13). The ANP mRNA
upregulation was significantly reduced by eplerenone after 30 days of treatment but not after 14 days (Table 13 ) .

Table 11. Effects of aldosterone + salt treatment alone or in combination with eplerenone in rats after 7 days of treatment Fina Left Right Left Right 1 Tibia entricle Ventricle .
VentriVentri ANp Grou Body cle cle Lengt Weight Weight p / /

Weig h Tibia Tibia U A
~

ht WeightWeight (cm) Length Length , (g) (mg) (mg) (mg/mm) (mg/mm) 2715 3.80 Vehicle 66719 1785 .01 1755 471 .
-+ salt (n_1 (n=10)(n=10) (n=10 (n=10) (n=10) 38 0) (n=10) Aldoster 2775 73625 3.80 8 .
one + (n=7 * 1837 -03 1946* 482 .
51*

salt ) (n=g) (n=8) (n=g) (n=8) (n=8) (n=g) Eplereno 2874 3.80 ne + 2.770.
* 71420 1825 01 1885 481 aldoster . 49 (n=9 (n=10)(n=10) (n=10 (n=10) (n=10) one +
) (n=10) salt ) Values are mean ~ SEM measured after 7 days of treatment.
*Significantly different from vehicle + salt control, p<0.05.
#Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.
AU = arbitrary units, measured relative to cyclophilin expression.
Table 12. Effects of aldosterone + salt treatment alone or in combination with eplerenone in rats after l4ays of treatment Left Right Left Right Final VentriVentr Tibia VentricleVentricle , A
p Body cle icle Lengt Weight Weight ~p Grou / / , ~gN
Weigh Weigh h Tibia Tibia A

t (g) Weightt (cm) Length Length (AU) (mg) (mg) (mg/mm) (mg/mm) 3115 1981 3.80 76~'0 Vehicle 74825 0 .01 1954 523 .
(n=12 ~

+ salt (n=13)(n=13 (n=13 (n=13) (n=13) 66 (n=10) Aldoster 01 81722 1895 = 6.701.
8+0 1* .02 2145* 501 (n=12 (n~12 (n=12 (n=12) (n=12) n9 salt (n ( 12) 9) Eplereno 2836 1971 3.80 ne + 81322 6.642.

aldoster * * 9 .02 2146* 525 (n 11 (n (n=11) (n=11) 11 (n 11 one +
~ (n=11)~ ~ _ (n 10) salt Values are mean ~ SEM measured after 14 days of treatment.
* Significantly different from vehicle + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.
AU = arbitrary units, measured relative to cyclophilin expression.
Table 13. Effects of aldosterone + salt treatment alone or in combination with eplerenone in rats after 30 days of treatment Left Right Left Right Final Ventr Ventr entricle Ventricle Bod icle icle Tibia Weight Weight y / /

Group Weigh weigh Weigh LengthTibia Tibia ~'NA

(em) (AU) fig) t t Length Length (mg) (mg) (mg/nun) (mg/~) Vehicle + salt 3148 7052 1676 4 1725 411 0-73+_0.2 (n=8) 03 Aldoste rove 2721 9102 1928 3.90. 20.173.
+

salt p* g* * 02* 2337* 492* 36*

(n=9) Epleren one +

aldoste # 9363 1986 3.90. 9.202.4 3317 2409* 512* #

rone 4* * 00* 4*
+

salt (n=9) Values are mean ~ SEM measured after 30 days of treatment.
*Significantly different from vehicle + salt, p<0.05.
# Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.

AU = arbitrary units, measured relative to cyclophilin expression.
Myocardial Fibrosis Interstitial collagen volume fraction and hydroxyproline levels were not statistically different at any time point among the experimental groups (Tables 14-16). A
modest increase in collagen type-I message was detected in aldosterone + salt and aldosterone + eplerenone +
salt treatment at 30 days, compared to vehicle + salt controls (Table 16). Collagen type III mRNA levels were not significantly increased at any time point (Tables 14-16).
Table 14. Effects of aldosterone + salt treatment alone or in combination with eplerenone on myocardial injury and fibrosis in rats after 7 days of treatment yocardia ydroxypro ollagen-1 ICVF line I Collagen-Group Necrosis (o) III (AU) (p_4) (N~g/m9') (AU) 4.40 3.570.4 1.100.
0'00.0 -5 090 Vehicle + salt (n=10) 5 15 .
.
(n=10) (n=10 (n=10) (n=10) Aldosterone 0.00.0 5-60 2.730.3 1.360. 1.420.12 +

n-8) .6 4 14 _ salt ( (n 8) (n=6) (n=8) (n=8) Eplerenone + 5-40 3.060.3 0 0.00.0 .6 . 1,090.21 aldosterone 6 .
+ 15 (n=10) (n=10 (n=10) salt ) (n=10) (n=10) Values are mean ~ SEM measured after 7 days of treatment.
Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction.
Collagen-I = Collagen type I mRNA.
Collagen-III = Collagen type III mRNA.
AU=arbitrary units, measured relative to cyclophilin expression.

Table 15. Effects of aldosterone + salt treatment alone or in combination with eplerenone on myocardial injury and fibrosis in rats after 14 days of treatment yocardia ydroxypr 1 ICVF line ollagen- Collagen-Group Necrosis (%) I (AU) III (AU) ( !~g/m9' ' ) 4.70 Vehicle + 0.00.0 .4 3.260.2 1.080. 1,010.10 salt (n=13) 4 10 (n=13 (n=13) (n=10) (n=10) 5.10 Aldosterone 0 . 80 , 5 4 . 040 1 . 240 1 _ ~B...E.O., + . 3 0 . 4 . 14 salt (n=12) (n=12 (n=9) (n=12) (n=9) Eplerenone 4.50 + 4.460.5 1 0.50.2 ,3 . 1,610.26 aldosterone 0 .
+ 21 (n=11) (n=11 (n=11) salt ) (n=11) (n=11) Values are mean ~ SEM measured after 14 days of treatment.
Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction.
Collagen-I = collagen type I mRNA.
Collagen-III - collagen type III mRNA.
AU = arbitrary units, measured relative to cyclophilin expression.
Table 16. Effects of aldosterone + salt treatment alone or in combination with eplerenone on myocardial injury and fibrosis in rats after 30 days of treatment yocardia ydroxypro ollagen-1 ICVF line Collagen-I

Group Necrosis (%) III (AU) (N~g/mg) (AU) Vehicle + salt 6.20 3.980.6 1 .
(n=8) 0.00.0 5 . 0-910.12 .5 13 Aldosterone 2.00.4 7.91 4.390.6 2.290.
+

salt (n=9) * .0 2 47* 1.390.20 Eplerenone +

Aldosterone 0.00.0# 6.20 4.100.5 2.530. 1,530.23 +

salt (n=9) .5 3 20*

Data are mean ~ SEM measured after 30 days of treatment.
* Significantly different from vehicle, p<0.05.
# Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction Collagen-I = collagen type I mRNA.
Collagen-III = collagen type III mRNA.
AU = arbitrary units, measured relative to cyclophilin expression.
Myocardial Histopathology Myocardial tissue damage was evaluated after 7, 14, and 30 days of treatment using a semi-quantitative scoring system. Hearts from vehicle + salt controls were histologically normal at all timepoints. No vascular or myocardial lesions were identified in hearts from rats receiving aldosterone + salt after 7 days of treatment (Table 14). In contrast, focal arterial and myocardial alterations were observed starting at 14 days of treatment (Tables 15 and 16). Qualitative changes in the arteries and myocardium were similar after 14 days and 30 days of aldosterone + salt treatment, but the frequency and severity increased with time.
Administration of eplerenone markedly attenuated myocardial injury at all time points (Tables 14-16; Fig.
44) .
Gene Expression of Inflammatory Mediators The expression levels of multiple proinflammatory molecules were assessed using quantitative Taqman PCR
analysis (Tables 17-19). Expression levels of cyclooxygenase-2 (COX-2) and monocyte chemoattractant protein-1 (MCP-1) were similarly and significantly increased by aldosterone + salt treatment at all time points. Osteopontin expression was also markedly upregulated after 14 days (~6-fold) and 30 days (~13-fold) of aldosterone + salt treatment (Tables 18-19).
Transforming growth factor beta one (TGF-~o, mRNA levels were not upregulated at any of the time points examined.
Intracellular adhesion molecule-1 (ICAM-1) mRNA
expression was upregulated at day 14 and 30 of aldosterone + salt treatment, although increases were modest (Tables 9-10). Gene expression for vascular cell adhesion molecule-1 (VCAM-1) was increased two-fold at day 30 of aldosterone + salt treatment, however this increase did not reach statistical significance (Table 19). Expression of all marker genes was significantly reduced by eplerenone compared to gene expression in animals treated with aldosterone + salt.
Table 17. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the inflammatory markers in rats after 7 days of treatment COX-2 Osteopo MCP-1 TGF-~i1 ICAM VCAM

ntin Group mRNA mgNA mRNA mRNA mRNA

(AU) ~ (AU) (AU) (AU) (AU) U p' , 1.060 1.120 1.07'0. 0.980 1.020 0:960 Vehicle + .18 17 .12 .12 .14 salt (n=6) ~16 (n=5) (n=10 (n=5) (n=5) (n=5) ) Aldosterone 2-220 1.910 2.380.1 1.350 1.220 1.550 .29* .51 7* .09 .10 .39 + salt (n=8) (n=8) (n=8) (n=8) (n=8) (n=8) Eplerenone 1.250 0.750 1.560.2 0.990 0.830 0.560 +

.27 .12 5 # .12 .10 .08 #

aldosterone (n=8) (n=8) (n=8) (n=10 (n=7) (n=6) + salt ) Values are mRNA expression means in arbitrary units ~
SEM after 7 days of treatment (relative to cyclophilin expression).

* Significantly different from vehicle + salt, p<0.05.
# Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
COX-2=cyclooxygenase-2.
MCP-1=monocyte chemoattractant protein-1.
TGF-(31= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1.
VCAM=vascular cell adhesion molecule-1.
Table 18. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the inflammatory markers in rats after 14 days of treatment COX-2 OsteopontMCP-1 TGF-ail ICAM VCAM

Group ANA , mRNA mRNA mRNA mRNA

(AU) ~N (AU) (AU) (AU) (AU) A

(AU) 1.070 1.130. 1.040 1.020 1.120 0.970 Vehicle .15 .08 .07 .07 .11 +

salt (n=7) 08 (n=7) (n=10 (n=7) (n=5) (n=7) ) Aldosteron 4'340. 6.561.3 2.760. 1.270 1.470 1.160 72* 7* 32* .16 .12* .19 a + salt (n=g) (n=8) (n=8) (n=9) (n=8) (n=8) Eplerenone 1.260 0.830 2.020. 2.940.7 1.590. 1 + 49* # 2 # * 10* # .16 . .10 .09#

aldosteron (n=11) (n=11) (n=11) (n~11 (n=11) (n~ll a + salt Values are mRNA expression means in arbitrary units ~
SEM after 14 days of treatment (relative to cyclophilin expression).
* Significantly different from vehicle + salt, p<0.05.
# Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
COX-2=cyclooxygenase-2.
MCP-1=monocyte chemoattractant protein-1.
TGF-(31= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1.
VCAM=vascular cell adhesion molecule-1.

Table 19. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the inflammatory markers in rats after 30 days of treatment COX-2 Ostt I,qCP-1 TGF-ailICAM VCAM
opon Group mRNA , mRNA mRNA mRNA mRNA

(AU) ~N (AU) (AU) (AU) (AU) A

(AU) Vehicle + 1-110.1 0.990.1 1,220.2 1.010 1.230. 1.140.

1 1 7 .13 25 25 salt (n=7) (n=7) (n=8) (n=6) (n=5) (n=7) Aldosterone 4.530.9 13.271. 4.541.2 1.330 1.810. 2.140.

2* 43* 5* .16 22* 49 + salt (n=6) (n=6) (n=6) (n=9) (n=5) (n=5) Eplerenone 2-2g0,3 2.590.8 2.290.4 1.320 1.220. 1.040.
+

aldosterone 3* # 2* # 2* # .11 15 # 14#

+ (n=9) (n=9) (n=9) (n=9) (n=8) (n=9) lt sa Values are mRNA expression means ~ SEM after 30 days of treatment (relative to Cyclophilin expression).
* Significantly different from vehicle + salt, p<0.05.
Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
COX-2=cyclooxygenase-2.
MCP-1=monocyte chemoattractant protein-1.
TGF-(31= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1.
VCAM=vascular cell adhesion molecule-1.
Immunohistochemistry The molecular analysis of the aldosterone + salt-induced proinflammatory response was further characterized using immunohistochemical analysis. The majority of cells adhering to the endothelium and infiltrating the perivascular space stained positive for a monocyte/macrophage antibody (ED-1) and negative for a T-cell antibody (CD-3). Significant expression of osteopontin was evident in hearts from aldosterone +

salt treated rats, compared with the absence of osteopontin staining in hearts from vehicle + salt controls. Osteopontin expression was primarily localized to medial cells of affected and some unaffected coronary arteries, but was also present in some macrophages in the perivascular space and areas of myocardial necrosis. No evidence of significant osteopontin expression was found in cardiomyocytes.
ICAM-1 staining was identified in endothelial cells and in the perivascular space; however, VCAM-1 was primarily expressed in endothelial cells. Administration of eplerenone markedly blunted the aldosterone + salt treatment induced staining in myocardial tissue for all marker proteins evaluated.
In-situ Hybridization for Osteopontin mRNA
In-situ hybridization was performed to localize osteopontin expression in myocardial tissue. The majority of osteopontin mRNA was found in the medial cells of coronary arteries (Figure 3); however, osteopontin message was also identified in perivascular cells and cells infiltrating ischemic and necrotic areas. Osteopontin mRNA was not evident in cardiomyocytes_or in unaffected interstitial areas.
CONCLUSION
Treatment of rats with aldosterone in the presence of salt induced vascular inflammation and cardiac tissue damage. This damage induced by aldosterone + salt treatment was preceded by an inflammatory response that was characterised by the upregulation of proinflammatory molecules. Eplerenone markedly attenuated this initial vascular inflammatory response and subsequent myocardial ink ury .
Renal Hypertensive Rat Model A combination therapy of an aldosterone inhibitor and a cyclooxygenase-2 selective inhibitor may be evaluated for blood pressure lowering activity in the renal-artery ligated hypertensive rat, a model of high renin hypertension. In this model, six days after litigation of the left renal artery, both plasma renin activity and blood pressure are elevated significantly (J. L. Cangiano et al, J. Pharmacol. Exp. Ther., 206, 310-313 (1979)). Male Sprague-Dawley rats are instrumented with a radiotelemetry blood pressure transmitter for continuous monitoring of blood pressure.
The rats are anesthetized with a mixture of ketamine-HCl (100 mg/kg) and acepromazine maleate (2.2 mg/kg). The abdominal aorta is exposed via a midline incision.
Microvascular clamps are placed on the aorta distal to the renal arteries and the iliac bifurcation. The aorta is punctured with a 22-gauge needle and the tip of a catheter is introduced. The catheter, which is held in place by a ligature in the psoas muscle, is connected to a radiotelemetry blood pressure transmitter (Mini-Mitter Co., Inc., Sunriver, OR). The transmitter is placed in the peritoneal cavity and sutured to abdominal muscle upon closing of the incision. Rats are housed singly above a radiotelemetry receiver and are allowed standard rat cho and water ad libitum. At least five days are allowed for recovery from surgery. Mean arterial pressure and heart rate are measured on a data recorder as is appropriate, such as a mini-computer. Data Data are sampled for 10 seconds at 200-500 Hz at 2.5 to 10 min intervals 24 hours per day. After collecting control data for 24 hours, the rats are anesthetized with methohexital (30 mg/kg, i.p.) and supplemented as needed. A midline abdominal incision is made, approximately 2 cm in length to expose the left kidney.
The renal artery is separated from the vein near the aorta, with care taken not to tramatize the vein. The artery is completely ligated with sterile 4-O silk. The incision is closed by careful suturing of the muscle layer and skin. Six days later, when MAP is typically elevated by 50-70 mmHg, an aldosterone antagonist or a combination with one or more Cyclooxygenase-2 selective inhibitors are administerd by gavage each day for about 8 weeks. Single drug dosing is carried out using 20 and 200 mg/kg/day of the aldosterone inhibitor (for example, eplerenone) and 1, 3, 10, 30, and 100 mg/kg/day of the cycloogenase-2 selective inhibitor. Drug mixtures are obtained by administering a combination of a dose of 1, 3, 10, 30, or 100 mg/kg/day of the cycloogenase-2 selective inhibitor with a dose of either 20 or 200 mg/kg/day of the aldosterone inhibitor. Blood pressure lowering is monitored by the radiotelemetry system and responses with the compounds are compared to a response obtained in vehicle-treated animals. Plasma and urinary sodium and potassium levels are monitored as a measure of the effectiveness of the aldosterone blockade. Urine samples are collected overnight using metabolic cages to isolate the samples. Plasma samples are obtained by venous catheterization. Sodium and potassium are measured by flame photometry. Cardiac fibrosis is determined by histological and chemical measurements of the excised hearts following perfusion fixation. Left and right ventricles are weighed, embedded, and sectioned. Subsequently, sections are stained with picrosirius red and the red staining collagen areas are quantitated by computerized image analysis. The apex of the heart is acid digested and the free hydroxyproline measured colorimetrically. It is expected that MAP will be significantly lowered toward normal pressures in the test animals, treated with the combination therapy and that the condition of myocardial fibrosis will be arrested or avoided.
Several other animal models are available which are appropriate for evaluation of prevention of cardiovascular conditions including the prevention of atherosclerosis. See Stehbens, Prog. Card. Dis., XXIX, 1007-28 (1986) and Zhang et al., Science, 258, 468-71 (1992) .
An APOe mouse model for atherosclerosis has been described by Roselear et al. (Arterioscle. Thromb. Vasc.
Biol., 16, 1013-18 (1996)). The aldosterone blocker should be active in preventing atherosclerotic lesions.
The biological evaluations described herein are useful in demonstrating the efficacy of combination therapies comprising an aldosterone receptor antagonist, and a NSAID, for the treatment or prevention of a cardiovascular disorder.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.
All patent documents referenced herein are incorporated by reference.

Claims (69)

What Is Claimed Is:

1. A combination for the treatment or prevention of a cardiovascular disorder comprising a first amount of an aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said NSAID.

2. A pharmaceutical composition for the treatment or prevention of a cardiovascular disorder comprising a first amount of an aldosterone receptor antagonist, a second amount of a NSAID, and one or more pharmaceutically acceptable carrier materials, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said NSAID.

3. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is an epoxy-steroidal aldosterone receptor antagonist.

4. The pharmaceutical composition of Claim 3 wherein said epoxy-steroidal aldosterone receptor antagonist has an epoxy moiety fused to the "C" ring of the steroidal nucleus of a 20-spiroxane compound.

5. The pharmaceutical composition of Claim 4 wherein said 20-spiroxane compound is characterized by the presence of a 9.alpha.-,11.alpha.-substituted epoxy moiety.

6. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is selected from the group consisting of:
Eplerenone;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, (7.alpha.,11.alpha.,17.beta.)-;
3'H-cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.alpha.,7.beta.,11.alpha.,17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-methylethyl) ester, monopotassium salt, (7.alpha.,11.alpha.,17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7.alpha.,11.alpha.,17.beta.)-;
3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.beta.,7.beta.,11.alpha.)-;
3'H-cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6.beta.,7.beta.,11.alpha.,17.alpha.)-;
3'H-cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6.beta.,7.beta.,11.alpha.,17.beta.)-;
3'H-cyclopropa[6,7]pregna-4,6-dime-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.beta.,7.beta.,11.alpha.,17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, .gamma.-lactone, ethyl ester, (7.alpha.,11.alpha.,17.beta.)-; and Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, .gamma.-lactone, 1-methylethyl ester, (7.alpha., 11.alpha., 17.beta.)-.

7. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is eplerenone.

8. The pharmaceutical composition of Claim 7 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.

9. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, and ibuprofen.

10. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone.

11. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.

12. The pharmaceutical composition of Claim 8 wherein said NSAID and said aldosterone receptor antagonist are present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said NSAID to said aldosterone receptor antagonist.

13. The pharmaceutical composition of Claim 12 wherein said weight ratio range is from about one-to-five to about one-to-fifteen.

14. The pharmaceutical composition of Claim 12 wherein said weight ratio is about one-to-ten.

15. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is spironolactone.

16. The pharmaceutical composition of Claim 15 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.

17. The pharmaceutical composition of Claim 16 wherein said NSAID and said aldosterone receptor antagonist are present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said NSAID to said aldosterone receptor antagonist.

18. The pharmaceutical composition of Claim 17 wherein said weight ratio range is from about one-to-five to about one-to-fifteen.

19. The pharmaceutical composition of Claim 18 wherein said weight ratio is about one-to-ten.

20. The pharmaceutical composition of Claim 2 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.

21. A method for the treatment or prevention of a cardiovascular disorder in a subject in need thereof comprising administering to the subject a first amount of an aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said NSAID.

22. The method of Claim 21 wherein the cardiovascular disorder is selected from the group consisting of hypertension, heart failure, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification and inflammation.

23. The method of Claim 21 wherein the cardiovascular disorder is selected from the group consisting of coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification and inflammation.

24. The method of Claim 21 wherein said aldosterone receptor antagonist is a spirolactone-type compound.

25. The method of Claim 21 wherein said aldosterone receptor antagonist is spironolactone.

26. The method of Claim 26 wherein said NSAID
is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.

27. The method of Claim 26 wherein said NSAID
is selected from the group consisting of acetaminophen, diclofenac, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, and aspirin.

28. The method of Claim 21 wherein said aldosterone receptor antagonist is an epoxy-steroidal aldosterone receptor antagonist.

29. The method of Claim 28 wherein said epoxy-steroidal compound has an epoxy moiety fused to the "C" ring of the steroidal nucleus of a 20-spiroxane compound.

30. The method of Claim 29 wherein said 20-spiroxane compound is characterized by the presence of a 9-alpha, 11-beta-substituted epoxy moiety.

31. The method of Claim 28 wherein said epoxy-steroidal compound is selected from the group consisting of:
Eplerenone;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, (7.alpha.,11.alpha.,17.beta.)-;
3' H-cyclopropa[6, 7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.beta.,7.beta.,11.alpha.,17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-methylethyl) ester, monopotassium salt, (7.alpha.,11.alpha.,17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7.alpha.,11.alpha.,17.beta.)-;

3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.beta., 7.beta., 11.alpha.)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6.beta., 7.beta., 11.alpha., 17.beta.)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6.beta., 7.beta., 11.alpha., 17.beta.)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, .gamma.-lactone, (6.beta., 7.beta., 11.alpha., 17.beta.)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, .gamma.-lactone, ethyl ester, (7.alpha., 11.alpha., 17.beta.)-; and Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, .gamma.-lactone, 1-methylethyl ester, (7.alpha., 11.alpha., 17.beta.)-.

32. The method of Claim 21 wherein said aldosterone receptor antagonist is eplerenone.

33. The method of Claim 32 wherein said NSAID
is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.

34. The method of Claim 21 wherein the NSAID
is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.

35. The method of Claim 21 wherein said aldosterone receptor antagonist and said NSAID are administered in a sequential manner.

36. The method of Claim 21 wherein said aldosterone receptor antagonist and said NSAID are administered in a substantially simultaneous manner.

37. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 0.1 mg to about 400 mg.

38. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 1 mg to about 200 mg.

39. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 1 mg to about 100 mg.

40. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 10 mg to about 100 mg.

41. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 25 mg to about 100 mg.

42. The method of Claim 32 wherein said eplerenone is administered in a daily dose selected from the group consisting of 5 mg, 10mg, 12.5 mg, 25 mg, 50 mg, 75mg, and 100 mg.

43. The method of Claim 32 wherein said eplerenone is administered in a daily dose selected from the group consisting of 25 mg, 50 mg and 100 mg.

44. A method for the treatment or prevention of an inflammation-related disorder in a subject in need thereof comprising administering to the subject a first amount of an aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together are sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject.

45. The method of Claim 44 wherein said inflammation-related disorder occurs in a tissue of said subject.

46. The method of Claim 44 wherein said inflammation-related disorder occurs in an organ of said subject.

47. The method of Claim 46 wherein said organ is the heart.

48. The method of Claim 46 wherein said organ is the brain.

49. The method of Claim 46 wherein said organ is the kidney.

50. The method of Claim 44 wherein the increased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject.

51. The method of Claim 44 wherein the decreased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject.

52. The method of Claim 44 wherein two or more of said expression products are co-expressed simultaneously.

53. The method of Claim 44 wherein two or more of said expression products are co-expressed sequentially.

54. The method of Claim 44 wherein said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a v .beta.3, Inf-.gamma., IL-1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, TXA2, b-FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA, PAI-1, CRP, IL-6, IL-10, IL-12, Troponin T, HSP65, amyloid, Phospholipase A2, fibrinogen, CD40/CD40L, collagen binding integrin a1.beta.1 and collagen binding integrin a2.beta.1.

55. The method of Claim 44 wherein said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a v .beta.3, Inf-.gamma., IL-1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, TXA2, b-FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA and PAI-1.

56. The method of Claim 44 wherein said expression product is cyclooxygenase-2.

57. The method of Claim 56 wherein said cyclooxygenase-2 is co-expressed with one or more expression products selected from the group consisting of osteopontin, MCP-1, ICAM-1 and VCAM-1.

58. The method of Claim 44 wherein said expression product is osteopontin.

59. The method of Claim 58 wherein said osteopontin is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, MCP-1, ICAM-1 and VCAM-1.

60. The method of Claim 44 wherein said expression product is MCP-1.

61. The method of Claim 60 wherein said MCP-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and VCAM-1.

62. The method of Claim 44 wherein said expression product is ICAM-1.

63. The method of Claim 62 wherein said ICAM-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1 and VCAM-1.

64. The method of Claim 44 wherein said expression product is VCAM-1.

65. The method of Claim 64 wherein said VCAM-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and MCP-1.

66. A kit for the treatment or prevention of a cardiovascular disorder comprising an aldosterone receptor antagonist and a NSAID.

67. The kit of Claim 66 further comprising written instructions stating how the contents of said kit can be used by a subject.

68. The kit of Claim 67 wherein the written instructions further state how a subject can use the contents of said kit to obtain a therapeutic effect without inducing unwanted side-effects.

69. The kit of Claim 67 wherein the written instructions comprise all or a part of the product label approved by a drug regulatory agency for said kit.